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Abstract 
 
Natural products are chemical compounds that are synthesized by living organisms and 
have biological and pharmacological functions. Many natural products or their 
derivatives have been successfully developed as pharmaceuticals and have thus made 
great contributions to human health. However, there is still an urgent need for novel and 
more potent pharmaceuticals, largely due to the rapidly increasing incidence of drug 
resistance. Natural products and their derivatives continue to be an important source for 
the development of new drugs. Critical steps in the investigation of natural products 
include the dissecting of the biosynthesis pathways of these compounds and elucidating 
the biological processes affected by these compounds. These studies would facilitate the 
production of potential drugs through biosynthesis or semi-biosynthesis, and provide 
valuable guidance in engineering these compounds towards improved efficacy. In this 
dissertation I present such studies on several natural products produced by bacteria and 
plants.  
 
Teicoplanin is a glycopeptide antibiotic produced by Actinoplanes teichomyceticus and 
has been shown to be potent against many vancomycin-resistant strains. Such improved 
efficacy is mainly attributed to two special tailoring modifications that are unique for 
teicoplanin-type glycopeptide antibiotics and are catalyzed by a P450 monooxygenase, 
Orf6*, and an acyltransferase, Orf11*, respectively. The structural characterization of 
these two enzymes presented in Chapter 2 provides insight into the substrate specificity 
of both enzymes.  
 
4-coumarate-CoA and its derivatives represent the key branching point in the 
phenylpropanoid pathway in plants. They are the precursors to many molecules that are 
important either pharmaceutically or for plant development. Studies on 4-coumarate:CoA 
ligase (4CL), the enzyme that synthesizes 4-coumarate-CoA, are thus crucial for plant 
engineering and drug discovery. In Chapter 3, I present thorough biochemical and 
structural studies on a tobacco 4CL enzyme, and a successful example of engineering this 
enzyme.  
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Bis-(3’-5’) cyclic dimeric guanosine monophosphate (c-di-GMP) is a second messenger 
molecule that plays a vital role in the global regulation in bacteria. By binding to different 
effectors, it triggers diverse responses that confer adaptability to various environmental 
conditions. In the last chapter of this dissertation I present the structural characterization 
of a novel c-di-GMP effector PelD from Pseudomonas aeruginosa that is critical for the 
formation of pellicles. The PelD structures shown here reveal an unprecedented binding 
mode for c-di-GMP.  
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 1 
Chapter 1  Introduction1 
 
Human society has a long history of using natural substances derived from animals, 
plants, microbes, and minerals to treat and prevent diseases. For example, the plant 
Artemisia annua (sweet wormwood) has been used in traditional Chinese medicine for 
more than two thousand years as the treatment for many diseases, most notably malaria 
(Miller and Su, 2011). The exploration of such natural medications has been greatly 
advanced since the purification of morphine from Papaver somniferum (opium poppy) at 
a German pharmacy in 1804, which demonstrated that the pharmacologically active 
compounds can be purified from their natural sources (Hamilton and Baskett, 2000) 
(Figure 1-1). The active anti-malaria ingredient in Artemisia annua, namely artemisinin, 
was purified from the leaves of this plant in 1972 and has since been widely used for the 
treatment of malaria (Miller and Su, 2011) (Figure 1-1). Such chemical compounds that 
are produced by living organisms and found to have pharmacological or biological 
activities have been collectively named natural products. By the end of twentieth century, 
the major source of new drugs has been natural products and other compounds derived 
from natural products, including semi-synthetic natural product derivatives and synthetic 
compounds based on natural products (Newman et al., 2003; Koehn and Carter, 2005; Li 
and Vederas, 2009; Newman and Cragg, 2012). Apart from the two drugs mentioned 
above, more examples include antibiotics (penicillin, tetracycline), cholesterol-lowering 
agent (lovastatin), and anti-cancer drugs (descodermolide) (Figure 1-1). Although 
research and development of natural product-based drugs are facing more economic and 
technical challenges in recent years, there is still tremendous ongoing interest in this field 
and natural products continue to be the source and inspiration for drug discovery (Koehn 
and Carter, 2005; Li and Vederas, 2009; Newman and Cragg, 2012).  
 
                                                          
1
 Parts of this chapter are adapted from the following published articles with the permission from the 
respective publisher:  
 
Li, Z., Rupasinghe, S.G., Schuler, M.A., and Nair, S.K. (2011). Crystal structure of a phenol-coupling P450 
monooxygenase involved in teicoplanin biosynthesis. Proteins 79: 1728-1738. 
 
Li, Z., Chen, J.H., Hao, Y., and Nair, S.K. (2012). Structures of the PelD cyclic diguanylate effector 
involved in pellicle formation in Pseudomonas aeruginosa PAO1. J Biol Chem 287: 30191-30204. 
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Figure 1-1. Chemical structures of some examples of natural-product drugs. The name of 
the compound is shown below the structure. The pharmacological function is shown in 
blue text, below which is shown the producer organism.  
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 Research in natural products has emphasized dissecting the biosynthesis pathways of 
these compounds. Advances in genome sequencing and manipulation in the last 15 years 
have greatly facilitated the identification and isolation of the biosynthesis gene cluster of 
interesting natural products from various organisms (Challis, 2008; Li et al., 2009; 
Doroghazi et al., 2011). Understanding of the biosynthesis mechanism of natural products, 
however, is still challenging and requires a cooperative effort in many disciplines 
including microbiology, chemistry, and biochemistry, as demonstrated by recent work on 
phosphonate antibiotics (Cicchillo et al., 2009; Lee et al., 2010).  
 
Understanding the biological processes affected by natural products is also critical. Many 
natural products are secondary metabolites in the producer organisms. Investigating the 
interactions between these compounds and their producers, as well as their target 
organisms, provides important guidelines for a better understanding of their functions. 
For example, bis-(3’-5’) cyclic dimeric guanosine monophosphate (c-di-GMP) (Figure 
1-2) is a second messenger molecule produced by many bacteria. Recent studies revealed 
that c-di-GMP not only plays a vital role in the global regulation in the producer 
organisms (Ryder et al., 2007; Gjermansen et al., 2010; Li et al., 2012), but also is an 
important factor in triggering a series of responses in the target organisms (Burdette et al., 
2011; Huang et al., 2012; Ouyang et al., 2012; Shang et al., 2012; Shu et al., 2012; Yin et 
al., 2012).  
 
 
Figure 1-2. Chemical structure of c-di-GMP.  
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Notably, structural biology has played a crucial role in the investigation on natural 
products (Nair and van der Donk, 2011). Crystal structures of enzymes involved in the 
biosynthesis of natural products have provided a great deal of insight into the 
mechanisms of biosynthesis and mode of action of these compounds. Information on 
substrate specificity, catalysis mechanism, and compound-host interactions in the target 
organisms can all be investigated with the aid of crystal structures (Cicchillo et al., 2009; 
Lee et al., 2010; Burdette et al., 2011; Li et al., 2011; Huang et al., 2012; Li et al., 2012; 
Ouyang et al., 2012; Shang et al., 2012; Shu et al., 2012; Yin et al., 2012). Moreover, 
structural biology has also provided the framework for molecular docking and computer 
modeling in natural product based-drug development (Shoichet et al., 2002; Balamurugan 
et al., 2005; Dekker et al., 2005; Geromichalos, 2007; van Montfort and Workman, 2009).  
 
In this dissertation, I present my  research on the biosynthesis and function of three 
natural products, including teicoplanin (Li et al., 2011), 4-coumarate-CoA, and c-di-GMP 
(Li et al., 2012). For all these studies, I employed a combination of biochemical, 
biophysical, and structural biology approaches, with an emphasis on structural biology, in 
particular X-ray crystallography.  
 
 
Figure 1-3. Mechanism of action of glycopeptide antibiotics. M: N-acetylmuramyl-
pentapeptide. The pentapeptide is shown as spheres. G: N-acetylglucosamine. (A) 
Crosslinks between the peptidoglycan layers in normal bacterial cell wall. (B) Single 
layer of peptidoglycan, with the binding target of glycopeptide antibiotics highlighted in 
dashed frame.  
 
Teicoplanin 
Many glycopeptides have been shown to have antibiotic activities. Glycopeptide 
antibiotics exert their antimicrobial activity against gram-positive bacteria by targeting 
the N-acyl-D-Ala-D-Ala peptide termini of peptidoglycan precursors and inhibiting cell 
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wall synthesis (Kahne et al., 2005) (Figure 1-3). One representative of this class of 
antibacterials, vancomycin (compound 1 in Figure 1-4), has been approved for clinical 
use and is used as the “last-resort” treatment against multiple-drug-resistant bacteria 
(Moellering, 2006), including methicillin-resistant Staphylococcus aureus (MRSA) 
(Anstead and Owens, 2004; Anstead et al., 2007) and drug-resistant pneumococci 
(Cunha, 2006). However, a considerable number of vancomycin-resistant bacteria have 
emerged, including vancomycin-resistant enterococci (VRE) (Murray, 2000) and 
vancomycin-intermediate and -resistant S. aureus (VISA and VRSA, respectively) 
(Hiramatsu et al., 1997; Sieradzki et al., 1999). There are various mechanisms for 
vancomycin resistance, one of which is outlined in Figure 1-5.  
 
 
Figure 1-4. Chemical structures of type I (1 vancomycin, 2 balhimycin), and type IV (3 
teicoplanin, 4 A47934, and 5 A40926) glycopeptide antibiotics. 
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Figure 1-5. Illustration of one example of vancomycin resistance mechanism. (A) The 
hydrogen bonds between vancomycin and an analog to its normal binding target, di-
acetyl-Lys-D-Ala-D-Ala. (B) The hydrogen bonds between vancomycin and an analog to 
its binding target in the resistant bacteria, di-acetyl-Lys-D-Ala-D-Lac. The loss of one 
hydrogen bond compared to the wild type strains results in over 1000-fold decrease in 
binding affinity (Kahne et al., 2005).  
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The lipoglycopeptide antibiotic teicoplanin (compound 3 in Figure 1-4) has proven 
efficacy against MRSA and VRSA (Van Bambeke, 2006), and has shown superior 
pharmacokinetic profile in comparison to vacomycin (Malabarba and Goldstein, 2005). 
The ability of teicoplanin to counter vancomycin resistant pathogens has prompted 
research efforts towards the design of lipoglycopeptide derivatives with increased 
antimicrobial properties relative to the parent compounds.  
 
The general structure of glycopeptide and lipoglycopeptide antibiotics consists of a 
heptapeptide backbone containing aromatic amino acids whose side chains are 
oxidatively coupled via biaryl or biarylether bridges to generate an aglycone core 
(Donadio et al., 2005) (Figure 1-4). These cross-links force the peptide backbone into a 
rigid conformation that is crucial to the primary antibiotic activity of glycopeptide 
antibiotics (Hadatsch et al., 2007). Previous studies have shown that linear or various 
mono-cyclic or bi-cyclic intermediates of the corresponding antibiotic have minimal 
antimicrobial activity (Pelzer et al., 1997; Süssmuth et al., 1999; Bischoff et al., 2001b; 
Bischoff et al., 2001a; Stegmann et al., 2006). The cross-linked aglycone undergoes 
further tailoring modifications including N-methylation, halogenation, glycosylation, 
and/or acylation (Hubbard and Walsh, 2003; Sussmuth and Wohlleben, 2004).  
 
The most distinguishing features of teicoplanin-type antibiotics compared to 
vancomycin-type antibiotics include an additional cross-link between residues 1 and 3 
and an N-acyl chain on the glucosamine group linked to residue 4 (Figure 1-4). These 
two modifications have been found to be greatly responsible for the superior 
pharmacokinetic profile of teicoplanin (Beauregard et al., 1995; Malabarba et al., 1997; 
Cooper and Williams, 1999; Dong et al., 2002).  In Chapter 2 of this dissertation, I 
present structural studies on the enzymes that catalyze these two modifications. These 
structures provide insight into the substrate specificity determinants of these enzymes and 
suggest possible catalysis mechanisms.  
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4-coumarate-CoA 
Many important natural products are made by plants as primary or secondary metabolites. 
The phenylpropanoid pathway represents the central biosynthetic nexus for the 
production of an array of plant metabolites including monolignols, phytohormones, 
flavonoids, and phenylpropenes (Hahlbrock and Scheel, 1989). The pathway directs the 
flow of carbon from primary metabolism to diverse secondary metabolism branch 
pathways. These phenylpropanoids serve a range of functions in planta, including 
providing mechanical support, UV protection, defense against pathogens, and mediating 
interactions with pollinators (Hahlbrock and Scheel, 1989; Lee and Douglas, 1996).  
 
 
 
Figure 1-6. Early steps in the phenylpropanoid pathway in plants.  
 
Several of these metabolites are also of pharmaceutical interest, including the stilbenoid 
resveratrol (lifespan extension) (Richard et al., 2011), the phenylpropene shikimol (a 
precursor in the synthesis of the entheogenic drug MDMA) (Gimeno et al., 2005), and the 
coumarin umbelliferone (antioxidant) (Kanimozhi et al., 2011). Lignin, the polymeric 
product of monolignols, has been the focus of research that targets agro-industrial uses of 
plant biomass (Boudet et al., 2003; Ragauskas et al., 2006). 
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The core reactions of the general phenylpropanoid pathway start with the deamination of 
phenylalanine (by phenylalanine ammonialyase) to yield trans-cinnamic acid (Figure 
1-6), which is then para-hydroxylated (by cinnamate-4-hydroxylase) to form 4-coumaric 
acid. A second hydroxylation at the C3 position of the phenolic ring (by coumarate 3-
hydrolase) affords caffeic acid. Caffeic acid can undergo O-methylation at C3 to yield 
ferulic acid or additional hydroxylation and O-methylation at C5 to yield sinapinic acid 
(Figure 1-7). A key branching point in the phenylpropanoid pathway is the formation of 
coenzyme A (CoA) thioesters of these hydroxycinnamic acid derivatives catalyzed by the 
enzyme 4-coumarate:CoA ligase (4CL, EC 6.2.1.12), which leads to the  productions of a 
variety of important molecules (Figure 1-6). 
 
 
Figure 1-7. Examples of hydroxycinnamic acids.  
 
4CL proteins play vital roles in regulating carbon flow in plant biosynthetic pathways, as 
their product hydroxycinnamate derived-CoA thioesters serve as precursors for various 
branching pathways of phenylpropanoid synthesis. For example, 4-coumaroyl-CoA is a 
substrate for the first committed step in flavonoid biosynthesis (Cukovic et al., 2001), and 
lignin monomers, including 4-coumaryl alcohol, corniferyl alcohol, and sinapyl alcohol 
(Figure 1-8), are derived from the hydroxycinnamoyl-CoA thioesters (Boerjan et al., 
2003). As the level and composition of lignin in plants largely determine the efficiency of 
biomass utilization (Boudet et al., 2003), 4-coumarate:CoA ligases have been studied 
extensively in efforts to produce engineered plants with improved biomass utility. 
Although successful studies have been reported recently (Kajita et al., 1997; Lee et al., 
1997; Hu et al., 1999), 4CL engineering remains challenging due to limited knowledge of 
its catalytic mechanism. In Chapter 3, I present a thorough biochemical and structural 
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studies on an 4CL isoform from tobacco. The results provide insights into the substrate 
specificity of 4CL enzymes and provide guidelines in 4CL engineering.  
 
 
Figure 1-8. Chemical structures of lignin monomers (monolignols). From left to right are 
4-coumaryl alcohol, corniferyl alcohol, and sinapyl alcohol, respectively. Lignin is the 
polymerization product of these three monomers.  
 
c-di-GMP 
Bis-(3’-5’) cyclic dimeric guanosine monophosphate (c-di-GMP) (Figure 1-2) is a central 
regulator, which functions as an intracellular second messenger. In bacteria, this molecule 
confers adaptability to various environmental conditions, by coordinating the transition 
between the motile planktonic state to a sessile state associated with biofilm production 
(Jenal and Malone, 2006; Hengge, 2009; Schirmer and Jenal, 2009). Specifically, c-di-
GMP stimulates the production of adhesins and exopolysaccharide matrix components 
and leads to biofilm formation to protect bacteria from host-defense, starvation conditions, 
and antibiotics (Ryder et al., 2007; Gjermansen et al., 2010). Additional roles for c-di-
GMP include control of cell cycle progression (Duerig et al., 2009), antibiotic 
biosynthesis (Fineran et al., 2007), and expression of virulence genes (Parsek and Singh, 
2003; Dow et al., 2006; Kulesekara et al., 2006; Tamayo et al., 2007). The bacterial 
signaling nodes that respond to the c-di-GMP message present targets for therapeutic 
intervention against pathogens. 
 
Similar to other second messenger pathways, the c-di-GMP control module can be 
generally divided into four components that govern signal generation, degradation, 
recognition, and targeting, respectively (Hengge, 2009). The level of the signal molecule 
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is dynamically regulated by the opposing activities of diguanylate cyclases (DGCs) and 
phosphodiesterases (PDEs), which synthesize and degrade c-di-GMP, respectively. DGC 
activity is attributed to proteins that contain a characteristic GGDEF domain (named for 
the single-letter amino acid nomenclature of essential active site residues), while PDE 
activity is associated with either enzymes that contain either an EAL or a HD-GYP 
domain (Ausmees et al., 2001; Paul et al., 2004; Schmidt et al., 2005; Ryan et al., 2006). 
Interestingly, many DGCs have been shown to be subject to allosteric product inhibition, 
which is often caused by c-di-GMP binding to the so-called I-site in the GGDEF domain 
(Chan et al., 2004; Christen et al., 2006; De et al., 2009). The I-site is readily identified 
by the RxxD (Arg-X-X-Glu; where X is any amino acid) motif, which is connected N-
terminally to GGDEF motif through a five-residue linker. These two motifs are antipodal 
to each other in the three-dimensional structure as shown by the structures of PleD from 
Caulobacter vibriodes (Chan et al., 2004; Wassmann et al., 2007) and WspR from 
Pseudomonas aeruginosa (De et al., 2008; De et al., 2009).   
 
Direct recognition of the c-di-GMP signal occurs through an effector component that is 
often linked to a signal input component that regulates cellular functions at transcriptional, 
translational, or post-translational levels (Weber et al., 2006; Merighi et al., 2007; Monds 
et al., 2007; Duerig et al., 2009). Strikingly, c-di-GMP effectors are highly diverse and 
are responsible in the diversity of the cellular functions and processes controlled by c-di-
GMP in bacteria (Hengge, 2009; Schirmer and Jenal, 2009). Several classes of c-di-GMP 
effectors have been identified through in vivo and in vitro studies, and some have been 
structurally characterized. A novel class of c-di-GMP effector consists of molecules that 
can bind c-di-GMP through an RxxD motif that resembles the I-site of GGDEF domain 
of DGCs, but do not show catalytic activity as their active sites lack the requisite GGDEF 
motif. Examples include PelD from P. aeruginosa (Lee et al., 2007), CdgG from V. 
cholera (Beyhan et al., 2008), and PopA from C. vibriodes (Duerig et al., 2009). In 
contrast to the effectors described in the previous paragraph, biochemical data for I-site-
containing c-di-GMP effectors is sparse, and there are no crystal structures available for 
any members of this receptor class. In the last chapter of this dissertation, I present 
biochemical and structural studies on such a c-di-GMP effector. The results reveal a 
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novel binding mode of c-di-GMP by its effector and implied possible mechanisms for 
signal transduction in bacteria.  
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Chapter 2  Structural studies of a P450 monooxygenase and two acyltransferases 
involved in the biosynthesis of teicoplanin-type glycopeptide 
antibiotics
1
 
 
Abstract 
The lipoglycopeptide antibiotic teicoplanin has proven efficacy against gram-positive 
pathogens. Teicoplanin is distinguished from the vancomycin-type glycopeptide 
antibiotics, by the presence of an additional cross-link between the aromatic amino acids 
1 and 3 that is catalyzed by the cytochrome P450 monooxygenase Orf6* (CYP165D3), 
and an acyl chain on a sugar moiety added by an acyltransferase Orf11* (tAtf).  As a goal 
towards understanding teicoplanin biosynthesis, I present the biochemical and structural 
characterization of recombinant Orf6* from the teicoplanin producer Actinoplanes 
teichomyceticus. I also present the structures of tAtf from the same strain and its homolog, 
aAtf from nonomuraea, the producer of a teicoplanin-type glycopeptide A40926, in 
complex with octanoyl-CoA. The structure of Orf6* reveals the core fold common to 
other P450 monooxygenases but also shows novel features in the disposition of 
secondary structure elements near the active site cavity necessary to accommodate its 
complex heptapeptide substrate.  The complex structures tAtf and aAtf display a circular 
binding tunnel for the acyl chain and explain the acyl chain specificity.  These structures 
provide further insights into the mechanism of the biosynthesis of teicoplanin-type 
glycopeptide antibiotics.  
 
Introduction 
Glycopeptide antibiotics exert their antimicrobial activity against gram-positive bacteria 
by targeting the N-acyl-D-Ala-D-Ala peptide termini of peptidoglycan precursors and 
inhibiting cell wall synthesis (Kahne et al., 2005). One representative of this class of 
antibacterials, vancomycin (compound 1 in Figure 1-4), has been approved for clinical 
use and is used as the “last-resort” treatment against multiple-drug-resistant bacteria 
                                                          
1
 Parts of this chapter are adapted from the following published article with the permission from the 
publisher:  
 
Li, Z., Rupasinghe, S.G., Schuler, M.A., and Nair, S.K. (2011). Crystal structure of a phenol-coupling P450 
monooxygenase involved in teicoplanin biosynthesis. Proteins 79: 1728-1738. 
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(Moellering, 2006), including methicillin-resistant Staphylococcus aureus (MRSA) 
(Anstead and Owens, 2004; Anstead et al., 2007) and drug-resistant pneumococci 
(Cunha, 2006). However, a considerable number of vancomycin-resistant bacteria have 
emerged, including vancomycin-resistant enterococci (VRE) (Murray, 2000) and 
vancomycin-intermediate and -resistant S. aureus (VISA and VRSA, respectively) 
(Hiramatsu et al., 1997; Sieradzki et al., 1999). The lipoglycopeptide antibiotic 
teicoplanin (compound 3 in Figure 1-4) has proven efficacy against MRSA and VRSA 
(Van Bambeke, 2006), and has shown superior pharmacokinetic profile in comparison to 
vancomycin (Malabarba and Goldstein, 2005). The ability of teicoplanin to counter 
vancomycin resistant pathogens has prompted research efforts towards the design of 
lipoglycopeptide derivatives with increased antimicrobial properties relative to the parent 
compounds.  
 
The general structure of glycopeptide and lipoglycopeptide antibiotics consists of a 
heptapeptide backbone containing aromatic amino acids whose side chains are 
oxidatively coupled via biaryl or biarylether bridges to generate an aglycone core 
(Donadio et al., 2005) (Figure 1-4). These cross-links force the peptide backbone into a 
rigid conformation that is crucial to the primary antibiotic activity of glycopeptide 
antibiotics (Hadatsch et al., 2007). Previous studies have shown that linear or various 
mono-cyclic or bi-cyclic intermediates of the corresponding antibiotic have minimal 
antimicrobial activity (Pelzer et al., 1997; Süssmuth et al., 1999; Bischoff et al., 2001b; 
Bischoff et al., 2001a; Stegmann et al., 2006). The cross-linked aglycone undergoes 
further tailoring modifications including N-methylation, halogenation, glycosylation, 
and/or acylation (Hubbard and Walsh, 2003; Sussmuth and Wohlleben, 2004).  
 
Oxidative cross-links 
The elucidation of biosynthesis gene clusters of several glycopeptides has established the 
general route of the complex structure assembly (Pelzer et al., 1999; Pootoolal et al., 
2002; Sosio et al., 2003; Li et al., 2004). The building blocks, which are mostly non-
proteinogenic amino acids, are assembled by nonribosomal peptide synthetase (NRPS) 
(Kahne et al., 2005). The electron-rich aromatic side chains facilitate oxidative cross-
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linking reactions, which are carried out by a series of cytochrome P450 monooxygenases 
(P450s). For example, in the vancomycin-type (type I) glycopeptide antibiotic balhimycin 
(compound 2 in Figure 1-4) system, three heme-dependent P450s (OxyA, OxyB, OxyC) 
are responsible for the three cross-links in the heptapeptide substrate (Bischoff et al., 
2001b; Bischoff et al., 2001a). Genetic and chemical analyses have defined the 
regiospecificity and timing of the oxidative phenol-coupling reactions in the balhimycin 
cluster (Süssmuth et al., 1999; Bischoff et al., 2001b; Bischoff et al., 2001a). The first 
cross-linking occurs between residues 4 and 6 (C-O-D ring) and is catalyzed by OxyB 
(Süssmuth et al., 1999; Bischoff et al., 2001b; Bischoff et al., 2001a), the second is 
between residues 2 and 4 (D-O-E ring) and is catalyzed by OxyA, and the third is 
between residues 5 and 7 (AB ring) and is catalyzed by OxyC (Süssmuth et al., 1999; 
Bischoff et al., 2001b; Bischoff et al., 2001a).  It has been suggested that the cross-
linking reactions occur when the heptapeptide is still attached to the peptidyl carrier 
domain (PCD) as a thioester through its carboxy-terminus (Puk et al., 2002). This is 
supported by the in vitro activity studies of OxyB (Woithe et al., 2007), using peptide 
substrates that are conjugated to a PCD domain. 
 
A distinguishing feature of teicoplanin-type (type IV) glycopeptide antibiotics is an 
additional cross-link between residues 1 and 3 (F-O-G ring), which, in contrast to 
vancomycin-like glycopeptides, consists of non-proteinogenic aromatic amino acids 
(Malabarba et al., 1986) (Figure 1-4). Consequently, there are four P450s in biosynthetic 
systems of teicoplanin and related lipoglycopeptides (Pootoolal et al., 2002; Sosio et al., 
2003; Li et al., 2004; Hadatsch et al., 2007), namely orf5*, 6*, 7*, and 9* in the 
teicoplanin cluster (Li et al., 2004).  While the different oxidative enzymes from the same 
biosynthetic cluster show only modest sequence identity (i.e. less than 40%), orthologous 
enzymes from different species are highly similar.  For example, Orf5*, 7*, and 9* from 
the teicoplanin gene cluster show strong sequence correspondence to OxyA, OxyB, and 
OxyC from the vancomycin cluster (similarity: 90%, 80%, 84%; identity: 78%, 72%, and 
74%).  This conservation has been used to infer function for the teicoplanin oxidative 
enzymes in catalyzing the cross-link between residues 2-4, 4-6, and 5-7, respectively (Li 
et al., 2004). The remaining P450, Orf6* (CYP165D3), is likely to be responsible for the 
 16 
additional cross-link between residue 1 and 3 that is unique to the teicoplanin aglycone 
(Li et al., 2004). Gene-knockout studies on the teicoplanin-type glycopeptide antibiotic 
A47934 (compound 4 in Figure 1-4) confirmed four P450 proteins that are responsible 
for the four cross-links in this type of compound and suggested a likely order of the four 
phenol-coupling reactions. Intriguingly, the additional 1-3 cross-link in A47934, 
catalyzed by the Orf6* orthologue StaG, is thought to be the second phenol-coupling 
reaction (Hadatsch et al., 2007).  
 
N-Acylation 
Another distinguishing feature of teicoplanin is the presence of an N-acyl chain on the 
glucosamine group linked to residue 4 (Figure 1-4), hence the name lipoglycopeptide. 
The superior pharmacokinetic profile of teicoplanin has been partly attributed to this N-
acyl group (Beauregard et al., 1995; Malabarba et al., 1997; Cooper and Williams, 1999; 
Dong et al., 2002). For example, it was suggested to be responsible for the antibacterial 
activity of teicoplanin against the VRE VanB strains (Dong et al., 2002). It was proposed 
that this hydrophobic acyl chain anchors teicoplanin onto the bacterial cell membrane 
(Beauregard et al., 1995; Cooper and Williams, 1999) and thus increases the local 
concentration of teicoplanin near the peptidoglycan layer of bacterial cell wall, leading to 
a higher efficiency in inhibiting cell wall synthesis. In contrast, the vancomycin-type 
antibiotics, which lack such acyl chains, are more freely distributed (Beauregard et al., 
1995; Cooper and Williams, 1999).  
 
Studies of teicoplanin biosynthesis gene cluster (Li et al., 2004; Sosio et al., 2004) in A. 
teichomyceticus lead to the identification of an acyltransferase Orf11* that is responsible 
for N-acylation in teicoplanin tailoring. The protein shared no significant sequence 
homology to proteins of known function and its role as an acyltransferase was proposed 
based on the fact that orf11* gene was adjacent to a glycosyltransferase gene orf10* in 
the teicoplanin biosynthesis gene cluster (Li et al., 2004). In vitro analysis confirmed its 
activity, with medium-to-long chain acyl-CoA molecules as the acyl donor substrate, and 
2-aminoglucosamine teicoplanin pseudoaglycone as the acyl acceptor substrate (Li et al., 
2004; Kruger et al., 2005). An Orf11* homolog involved the biosynthesis of another type 
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IV lipoglycopeptide antibiotic A40926 by nonomuraea species was also identified (Sosio 
et al., 2003) and was shown to have similar activity (Kruger et al., 2005). For simplicity, 
these two acyltransferase (Atf) homologs will be referred to as tAtf and aAtf, respectively.  
 
 
Figure 2-1. Acyl chains of the major species of teicoplanin (A) and A40926 (B). For the 
latter, each acyl chain has been identified in two different species.  
 
Notably, both teicoplanin and A40926 are naturally produced as a mixture of compounds 
that differ almost only in the identities of the acyl chains. Teicoplanin has mainly five 
species (Borghi et al., 1984) and four species have been isolated for A40926 (Goldstein et 
al., 1987). These species have acyl chains that range from 10 carbons to 12 carbons and 
have different saturation or branching mode (Figure 2-1). In agreement with such acyl 
chain diversity, both tAtf and aAtf have been shown to possess significant activity against 
a series of acyl-CoA substrates of the chain lengths ranging from 6 to 14 carbons, with 
the best substrate of tAtf being decanoyl (C10)-CoA and the best for aAtf being lauroyl 
(C12)-CoA (Kruger et al., 2005). Understanding the molecular rationale for such wide 
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substrate tolerance would be crucial for developing novel lipoglycopeptide antibiotics 
based on the framework of these Atfs and their substrates.  
 
Here we report the recombinant expression and characterization of Orf6* from the 
teicoplanin producer Actinoplanes teichomyceticus, and also tAtf and aAtf from the 
producers of teicoplanin and A40926, respectively. We present high resolution crystal 
structures of these proteins. The Orf6* crystal structure is the first structure for a P450 
responsible for the additional 1-3 cross-link in the teicoplanin-type glycopeptide 
antibiotics. A comparison with the available structures of the phenol-coupling 
monooxygenases (OxyB and OxyC) in vancomycin system reveals a possible mechanism 
for Orf6* regiospecificity. The structures of the Atfs shed light on the acyl-chain 
specificity of these enzymes.  
 
Experimental procedures 
Cloning, Protein Expression, and Purification of Orf6*, aAtf, and tAtf 
Actinoplanes teichomyceticus and nonomuraea were purchased from the American 
Tissue Culture Collection and used directly as a template for polymerase chain reaction 
amplifications without purification of the genomic DNA. The orf6*, aAtf, tAtf genes were 
cloned into pET28b (Novagen) for overexpression of each protein with an amino-
terminal hexahistidine affinity tag.  
 
For Orf6* protein production, the expression construct was transformed into the 
Escherichia coli Rosetta (DE3) strain. A pre-culture was grown overnight at 37 °C in 
Terrific Broth (TB) with kanamycin (50 g/ml) and chloramphenicol (34 g/ml) and 
used to inoculate (4%, v/v) 400 ml of TB medium with the antibiotics and the resultant 
culture was grown at 37° C in shaker flasks.  When the optical density at 600 nm (OD600) 
reached 0.5, -aminolevulinic acid was added to 0.15 mM.  Protein production was 
induced at OD600 of 1.0 with the addition of 0.5 mM isopropyl-1-thio--D-
galactopyranoside and growth was continued at 18° C.  A second aliquot of -
aminolevulinic acid was added (0.15 mM) 20 hours after induction, followed by another 
24 hours of growth before cell harvest.   
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For protein production of aAtf and tAtf, the expression constructs were transformed into 
the Escherichia coli Rosetta (DE3) strain. A pre-culture was grown overnight at 37 °C in 
Luria Broth (LB) with kanamycin (50 g/ml) and chloramphenicol (34 g/ml) and used 
to inoculate (0.3%, v/v) 1 L of TB medium with the antibiotics and the resultant culture 
was grown at 37° C in shaker flasks. When the optical density at 600 nm (OD600) reached 
0.5, protein production was induced with the addition of isopropyl-1-thio--D-
galactopyranoside to 0.5 mM and growth was continued at 18° C for 20 hours before cell 
harvest.  
 
The culture was harvested by centrifugation at 3,500 rpm for 25 minutes and the resultant 
pellet was resuspended in 20 mM Tris, pH 8.0, 1 M NaCl, 30 mM imidazole, and 10% 
(v/v) glycerol. Harvested cells were disrupted by four passes through an Avestin C5 
Emulsiflex French Press and insoluble aggregates and cellular debris were removed by 
centrifugation at 15, 000 rpm for 1 hour.  
 
Recombinant protein from the above-clarified supernatant was applied to a 10 ml Talon 
resin (Clontech) column that was charged with nickel sulfate and pre-equilibrated with 20 
mM Tris, pH 8.0, 1 M NaCl, 30 mM imidazole. After elution from the nickel affinity 
resin with 200 mM imidazole, the polyhistidine tag was removed with thrombin (1 
unit/mg, MP Biomedicals). The protein was dialyzed into 20 mM Tris, pH 8.0, 50 mM 
NaCl and applied to a 5 ml HiTrap Q column (GE Healthcare), and then eluted with a 
linear gradient of NaCl from 50 mM to 1 M over 60 ml. Orf6* was further purified by 
size-exclusion chromatography (Superdex 75 16/60, GE Healthcare) prior to 
crystallization.  
 
Selenomethionine-incorporated Orf6* was produced by the method of van Duyne et al. 
(Van Duyne et al., 1993) and purified in the same manner as described above. Protein 
concentration was estimated by Bradford assay. 
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UV-visible spectroscopy 
The UV-visible absorption spectra for Orf6* were measured with a Varian Cary 3 
double-beam spectrophotometer. After thermal equilibration at 25 C the baseline was 
zeroed between 200 and 900 nm and the UV-visible spectra of the substrate-free Orf6* 
(0.1 mg/ml in 20 mM HEPES, pH 7.5, 100 mM KCl) were recorded. The protein was 
reduced by addition of 2 mg of solid sodium dithionite and spectra were measured under 
the same condition. The reduced protein was divided into two tandem cuvettes (sample 
and reference) and CO was bubbled through the sample cuvette for 30 seconds, then the 
difference spectrum was measured. The protein-imidazole complex was generated by 
adding 100 mM imidazole to Orf6* in the same buffer and spectra were measured under 
the same condition.  
 
Orf6* Crystallization 
Orf6* crystals were grown by the hanging drop vapor diffusion method. 1 l (8 mg/ml in 
a solution containing 20 mM HEPES, pH 7.5, 100 mM KCl) protein was mixed with 1 l 
precipitant solution containing 0.2 M sodium acetate, 0.1 M Tris, pH 8.5, and 20%  (w/v) 
polyethylene glycol 4, 000. The mixture drop was equilibrated over a well containing the 
same precipitant solution at 8 °C, and crystals reached their maximum size after 3 days. 
Selenomethionine-incorporated Orf6* was crystallized under the same condition. The 
crystals were soaked in cryoprotectant solution containing the precipitant solution 
supplemented with 30% (v/v) glycerol anhydrous prior to vitrification in liquid nitrogen.  
 
Orf6* Phasing and Structure Determination 
Crystals of selenomethionine-incorporated Orf6* (SeMet Orf6*) consistently diffracted 
to higher resolutions, and was subsequently used for data collection and structure 
refinement. Diffraction data were collected to a limiting resolution of 2.2 Å at an 
insertion device line (LS-CAT-Sector 21 ID-D, Advanced Photon Source, Argonne, IL), 
and integrated and scaled using the HKL2000 (Otwinowski et al., 2003).  SeMet Orf6* 
crystals occupy space group P31 with unit cell parameters a = 74.3 Å, b = 74.3 Å, c = 
75.5 Å and contain one molecule per asymmetric unit.  A four-fold redundant data set 
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was collected to a limiting resolution of 2.2 Å (overall Rmerge 
highest resolution shell).   
Table 2-1. Data collection, phasing and refinement statistics of Orf6*. 
 
 SeMet Orf6* 
Data collection  
Space group P31 
Cell dimensions  
a, b, c (Å) 74.3, 74.3, 75.5 
Resolution (Å) 50-2.2 (2.28-2.2)
a
 
Rsym (%) 6.6 (29.7) 
 28.8 (4.8) 
Completeness (%) 96.2 (74.0) 
Redundancy 3.5 (3.1) 
Refinement  
Resolution (Å) 25.0-2.2 
Number of reflections 21,363 
Rwork / Rfree
b
 20.1%/25.7% 
Number of atoms  
Protein 2898  
Solvent  184 
Heme 43 
Average B value  
Protein 30.8 
Solvent 37.2 
NADP 25.2 
R.m.s deviations  
Bond angles (Å) 1.29 
Bond lengths () 0.011 
a
Highest resolution shell is shown in parenthesis. 
b
R- obs|-k|Fcalc obs|and R-free is the R value for a test set of reflections 
consisting of a random 5% of the diffraction data not used in refinement. 
 
 
Selenium sites were identified using HySS (Adams et al., 2002; Grosse-Kunstleve and 
Adams, 2003) and heavy atom parameters were further refined using PHENIX (Adams et 
al., 2002; Grosse-Kunstleve and Adams, 2003) to yield an initial figure of merit of 0.390 
to 2.2 Å resolution.  Solvent flattening further improved the quality of the initial map 
permitting 80% of the main chain and 35% of the side chain residues to be automatically 
built by PHENIX.  This initial model was further improved by automated building using 
ARP/wARP (Perrakis et al., 1999) to yield a model with nearly all of the main chain and 
70% of the side chains. The remainder of the model was fitted using XtalView (McRee, 
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1999) and further improved by rounds of refinement with REFMAC5 (Murshudov et al., 
1997) and manual building. Multiple rounds of manual model building were interspersed 
with refinement using REFMAC5 to complete structure refinement.  Cross-validation 
used 5% of the data in the calculation of the free R factor (Kleywegt and Brunger, 1996). 
The stereochemistry of the model was routinely monitored throughout the course of 
refinement using PROCHECK (Laskowski et al., 1996).  Relevant data collection and 
refinement statistics are summarized on Table 2-1. 
 
Results  
UV-visible Spectroscopy analysis of Orf6* 
Amino-terminally hexahistidine-tagged Orf6* was heterologously expressed in 
recombinant E. coli Rosetta (DE3) and purified from the soluble fraction by Ni-NTA 
affinity chromatography, and was further purified by anion-exchange and size-exclusion 
chromatography after thrombolytic removal of the affinity tag. As shown in Figure 2-2A, 
Orf6* gave characteristic UV-visible absorption spectra of P450 hemeprotein (Hill et al., 
1970).  Specifically, the UV-visible absorption spectrum of substrate-free Orf6* has a 
Soret band at 419 nm, and β and α peaks at 536 and 570 nm, respectively, as is typical of 
oxidized P450s in the low-spin ferric state. Reduction of substrate-free Orf6* with 
sodium dithionite shifts the Soret band to 424 nm, and β and α peaks at 530 and 565 nm, 
respectively. The CO difference spectrum of reduced protein shows a prominent peak at 
450 nm (Figure 2-2B). These spectra show that the purified Orf6* is in the oxidized form, 
and can be reduced with sodium dithionite. Addition of imidazole to substrate-free Orf6* 
leads to a typical red shift in the Soret band to 429 nm, and β and α peaks to 543 and 565 
nm indicating that imidazole binds to the heme iron (III) atom as an axial ligand (Zerbe et 
al., 2002; Pylypenko et al., 2003), a typical feature of P450 hemeproteins (Jefcoate, 
1978).  
 
 23 
 
Figure 2-2. UV-visible absorption spectra of Orf6*. (A) Curve 1 (green) shows the 
spectrum of substrate-free Orf6*; Curve 2 (blue), after reduction with sodium dithionite; 
and Curve 3 (red), after addition of imidazole. (B) The CO-difference spectrum of 
reduced Orf6* showing the characteristic absorbance at 450 nm. 
 
Overall Structure of Orf6* 
The structure of Orf6* was determined to 2.2 Å using single-wavelength anomalous 
scattering from crystals grown with selenomethionine-incorporated protein (relevant data 
collection and refinement statistics are given in Table 2-1). As shown in Figure 2-3A and 
B, Orf6* exhibits the typical overall structure and protein topography of most P450 
heme-proteins (Graham and Peterson, 1999). The protein has a triangular prism shape 
with predominantly α-helical secondary structure (see Figure 2-3B for a structure-based 
sequence alignment and secondary structure assignment) and the heme prosthetic group 
is embedded between the proximal L and distal I helices. The structure comprises 15 α-
helices and 6 -stands, and it can be roughly divided into α-rich and -rich regions.   
 24 
 
 
Figure 2-3. (A) Ribbon diagram showing the overall structure of Orf6*.  Important 
secondary structural elements discussed in the text include F and G helices (colored in 
pink), I helix (colored in blue), and Cys loop (colored in red).  The heme is shown in 
yellow sticks and the iron atom as a red sphere.  Other secondary structural elements are 
colored in cyan. (B) Structure-based multiple sequence alignment of the type IV 
glycopeptide cross-linking cytochrome P450 monooxygenases Orf6* (teicoplanin), StaG 
(A47934) and Dbv13 (A40926) with those of the type I glycopeptide  monooxygenases 
OxyB and OxyC (both from the vancomycin cluster).  Residues that are unique to Orf6* 
and may be catalytically relevant are shown with a green arrowhead. 
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When compared with the crystal structures of other P450s using DALI (Holm and 
Rosenstrom, 2010), Orf6* shows the highest structural similarity to OxyB (Zerbe et al., 
2002), OxyC (Pylypenko et al., 2003), P450nor (Park et al., 1997), CYP105P1 (Xu et al., 
2009), and CYP105D6 (Xu et al., 2010), among the substrate-free wild-type P450 
structures (Table 2-2).  
 
Table 2-2. Similarity of structure and sequence between Orf6* and other P450s. 
 
P450 name
a
 PDB
b
 code Z-score 
RMSD
c
 
Å 
Sequence 
identity % 
FG
d
 conformation 
relative to Orf6* 
OxyB 1lg9 44.9 2.2 38 Open 
CYP105 (MES) 2z36 44.8 1.9 32 Same 
OxyC 1ued 44.7 2.1 37 Open 
CYP105P1 (FLI) 3aba 43.8 2.5 36 Close 
CYP105P1 (PIM) 3e5k 43.6 2.0 35 Same 
P450nor 1rom 43.4 2.0 26 Same 
CYP105P1 3e5j 43 2.1 35 Same 
CYP105D6 3abb 42.8 1.9 33 Same 
a
P450s that show the highest structural similarity to Orf6*. Shown in parenthesis are bound 
substrates/ligands. MES: 2-(N-morpholino)-ethanesulfonic acid; FLI: Filipin I; PIM: 4-Phenyl-
1H-imidazole.  
b
Protein Data Bank. 
c
Root mean square deviation.  
d
F and G helices of the corresponding P450s.  
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Figure 2-4. (A) Interactions between residues from I helix and those from other 
secondary structural elements. The I helix is shown in cyan and residues are colored in 
magenta, other helices are shown in gray and residues in these helices are colored in 
green.  The heme is shown as a yellow stick, the iron shown as a maroon sphere, and the 
iron bound water as a gray sphere. Hydrogen bond interactions are shown as dash lines, 
next to which the distances are shown. (B) Active site of Orf6* showing critical catalytic 
residues and those interacting with the heme propionate groups. The I helix is shown in 
cyan, catalytically relevant residues conserved among type IV glycopeptide P450 
monooxygenases are shown in magenta, Cys332 and other heme interacting residues 
shown in green. Hydrogen bond interactions are shown as dash lines, next to which the 
distances are shown. 
 
Active Site Architecture of Orf6*  
Orf6* shows the conserved four-helix bundle core, formed by D, E, I, and L helices, with 
the heme group confined between the I and L helices (Figure 2-4A), and above the Cys-
ligand loop adjacent to the amino-terminus of the L-helix.  This Cys-ligand loop contains 
the P450 signature amino acid sequence FxxGxHxCxG, with the absolutely conserved 
Cys332 being the proximal ligand to the heme iron.  The iron atom is in the heme plane 
and its distance to the thiolate sulfur of Cys332 is 2.3 Å.  A solvent molecule, located 2.6 
Å from the heme iron, completes the coordination shell (Figure 2-4A), consistent with the 
low spin heme state of substrate-free Orf6* observed in the UV-visible spectra (Figure 
2-2). 
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The long I-helix spans the entire catalytic site and forms a wall above the heme pocket. In 
most P450s, two highly conserved and catalytically important residues, an acidic residue 
immediately followed by a threonine, are usually found in the I-helix over the pyrrole 
ring B of the heme group (Graham and Peterson, 1999; Denisov et al., 2005). In contrast, 
in Orf6*, the acidic residue is Glu229 but the residue immediately to its carboxy-terminus 
is Gln230 (Figure 2-4B).  This variation is not unprecedented as the corresponding 
residues in OxyB are Asp239-Asn240, with the latter forming hydrogen bonds with two 
water molecules in the active site (Zerbe et al., 2002).  Although the side chain of Gln230 
in Orf6* points to the heme group as in OxyB, there are no water molecules within 
hydrogen bonding distance to its backbone or side chain. This sequence variation is 
conserved at the corresponding place in the sequences of most of the phenol-coupling 
P450s involved in glycopeptide antibiotics biosynthesis (Figure 2-3C).  The Gln230 side 
chain might play a similar role to the hydroxyl group of the usual threonine in forming a 
proton delivery channel during catalysis (Denisov et al., 2005) or be involved in 
hydrogen bond interactions with the extended peptide substrate.   
 
In striking contrast to the small neutral amino acid (glycine or alanine) typically found 
three residues before the conserved acidic residue in the I-helix of P450s (Park et al., 
1997; Zerbe et al., 2002; Pylypenko et al., 2003; Oshima et al., 2004), Orf6* contains a 
methionine residue (Met226) (Figure 2-4B) at this position. The side chain of Met226 
points into the active site and the sulfur atom forms a hydrogen bond with the heme iron-
coordinating water molecule.  Although the function of Met226 is not yet clear, 
corresponding methionine residues are found in S. toyocaensis StaG and Nonomuraea sp. 
Dbv13 (Figure 2-3C), both of which are P450s cross-linking the side chains of the 
aromatic residues 1 and 3 in the type IV glycopeptide antibiotics A47934 and 
A40926(Pootoolal et al., 2002; Hadatsch et al., 2007), analogous to the Orf6* cross-
linking reaction in teicoplanin biosynthesis(Li et al., 2004). All other putative phenol-
coupling P450s in glycopeptide antibiotics biosynthesis have the more typical glycine or 
alanine at this position.  The conservation of this methionine residue suggests that it plays 
a role in regiospecificity of the 1-3 cross-linking reaction.  Attempts to carry out 
mutational analysis at Met226 are limited by the fact that attempts to produce the 
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synthetic, singly cross-linked, heptapeptide substrate coupled to a PCD domain have thus 
far been unsuccessful. 
 
The active site conformation of Orf6* is stabilized by a number of hydrogen bonds 
between residues from I-helix and those from other secondary structure elements (Figure 
2-4A).  Hydrogen bonds from the side chain carboxylate oxygens of the I-helix residues 
Glu229 and Asp213 to the backbone amides of the F-helix residue Arg165 and the G-
helix residue Arg192, mediate the interaction of the I-helix with the F and G helices. The 
side chain carboxylate oxygens of Glu215 from the I-helix form hydrogen bonds with the 
guanidine nitrogen atom of Arg89 from the N-terminal portion of the C-helix, and the 
hydroxyl group of Tyr82 from the B’-C loop, respectively. The C-D loop forms 
interaction with the I-helix through the hydrogen bond between the hydroxyl group of 
Tyr98 and the side chain carbonyl oxygen of the I-helix residue Asn223.  
 
 
Orf6* Substrate Binding Pocket Comparison with Known P450s 
A significant difference between the structures of Orf6* and other known P450s is in the 
orientation of F and G helices, which are believed to be important for substrate binding 
(Gotoh, 1992; Graham and Peterson, 1999; Denisov et al., 2005). Although the F and G 
helices in Orf6* are similar to those in OxyB (Zerbe et al., 2002) and OxyC (Pylypenko 
et al., 2003) in terms of length and fold, their relative orientations are significantly 
different. In particular, in Orf6* the F and G helices are rotated toward the active site, 
resulting in a much more closed substrate binding pocket (Figure 2-5A and B). This is 
unexpected because the Orf6* substrate, teicoplanin heptapeptide (Li et al., 2004), is 
nearly the same size as the vancomycin heptapeptide substrate of OxyB and OxyC 
(Pelzer et al., 1999; Zerbe et al., 2002; Stegmann et al., 2006) (Figure 2-5C).  While the 
relative orientation of the F and G helices are similar in OxyB and OxyC (as would be 
expected given that they both work on the same substrate), the orientation of the F and G 
helices in Orf6* is much more similar to that of P450nor (Park et al., 1997), a nitric acid 
reductase whose substrate is substantially smaller compared to the teicoplanin aglycone 
substrate of Orf6*.   
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Figure 2-5. (A) and (B) Orthogonal views of a least squared superposition of the crystal 
structure of Orf6* (in pink) with those of P450nor (in blue) and OxyB (in green).  Note 
that the F and G helices of Orf6* and OxyB deviate significantly, despite the fact that 
both enzymes work on large, peptidic substrates.  The F-G helices of Orf6* are in a 
closed conformation, similar to those observed in structures of P450s that work on small 
molecule substrates (e.g., P450nor). (C) A comparison of the substrates of Orf6*, OxyB 
and OxyC, which may provide a rationale for the positioning of the F and G helices in 
these enzymes.  Existing cross-links in the substrate are shown as shaded circles and an 
arrow indicates the target site for each enzyme.  
 
Prior analysis of the substrate binding pockets of OxyB and P450nor lead to the 
speculation that the larger size of the OxyB substrate dictated the need for the more open 
binding pocket (Zerbe et al., 2002). However, our structure of Orf6* suggests that the 
binding pocket capped by the F and G helices may not only be determined by the 
substrate size, but also its orientation. Orf6* catalyzes the cross-linking at the amino-
terminus of the teicoplanin heptapeptide (Li et al., 2004), while the target of OxyB is the 
bulky center of the vancomycin heptapeptide (Pelzer et al., 1999; Zerbe et al., 2002; 
Stegmann et al., 2006).  Consequently, the heptapeptide substrate must be positioned in 
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the active site in substantially different orientations to afford the regiospecificities of each 
individual enzyme. While OxyC carries out the coupling reaction at the carboxy-terminus 
of the vancomycin heptapeptide, the open conformation of this enzyme can also be 
understood in the context of substrate orientation. Previous gene inactivation studies have 
suggested that the OxyC reaction is the last coupling reaction in vancomycin biosynthesis 
(Pylypenko et al., 2003; Stegmann et al., 2006), so its substrate, which is cross-linked 
between residues 2-4 and 4-6, has a rigid wide conformation that requires an open 
binding site (Figure 2-5C).  In contrast, genetic studies of A47934 biosynthesis 
(Pootoolal et al., 2002; Hadatsch et al., 2007) imply that Orf6* catalyzes the second 
coupling reaction in teicoplanin biosynthesis.  As a result, the Orf6* substrate is cross-
linked only between residues 4-6 and the lack of a rigid structure in this substrate can be 
accommodated by a closed binding pocket in Orf6*. 
 
In the Orf6* structure, the side chain of Glu229 in the I-helix forms a hydrogen bond 
with the backbone amide group of Arg165 from the F-helix (Figure 2-4A). This 
interaction likely stabilizes the inward conformation of F-helix, which in turn rotates the 
G-helix toward the active site. Such an interaction is not found in OxyB, OxyC, or 
P450nor but the Glu and Arg residues are conserved in both StaG and Dbv13 (Figure 
2-3C), both of which catalyze similar 1-3 coupling during the biosynthesis of the 
teicoplanin-type glycopeptide antibiotics A47934 and A40926, respectively.  The F and 
G helices of Orf6* might undergo a further closure of the active site upon substrate 
binding, as has been observed in some structurally similar P450s (Table 2-2), such as 
CYP105P1 that binds the antifungal macrolide antibiotic filipin (Xu et al., 2009; Xu et 
al., 2010).  
 
Implications for Catalysis on PCD-coupled Substrate by Orf6*  
Studies by Robinson and co-workers established that such oxidative coupling reaction 
only occurs on substrate peptides attached as thioesters to the NRPS module (Puk et al., 
2002).  In the presence of a suitable electron source, purified recombinant OxyB can 
catalyze the 4-6 crosslink of a heptapeptide substrate conjugated to a peptide carrier 
domain (PCD) from the cognate NRPS through a thioester linkage (Woithe et al., 2007).  
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As the Orf6* 1-3 cross-linking reaction occurs at the amino-terminus of the peptide 
substrate, and the PCD conjugation is through a carboxy-terminal linkage, the substrate 
can be correctly registered in the active site without requiring neither the PCD domain 
nor the phosphopantetheine arm to be substantially wedged into the binding pocket.  In 
contrast, for the OxyB and OxyC reactions that occur at the center and carboxy-terminus 
of the peptide, their substrates are accommodated in an open binding pocket that is 
necessary to fit significant portions of both the heptapeptide substrate as well as the 
phosphopantetheine group (Figure 2-5C). 
 
In order to gain further insights into the determinants of substrate recognition, we docked 
the co-crystal structure of the P450(Biol)-tetradecanoic acid-acyl carrier protein (ACP) 
complex (Cryle and Schlichting, 2008) onto that of Orf6* (Figure 2-6A and B).  Despite 
the fact that P450(Biol) and Orf6* share less than 40% sequence identity, the ACP can be 
docked onto the structure of Orf6* without significant steric clashes.  Although the PCD-
peptide conjugate substrate of Orf6* is distinct from the tetradecanoic acid-ACP substrate 
of P450(Biol), this model yields a likely trajectory for the teicoplanin aglycone backbone.  
In this model, the unique Met226 present in Orf6* is located proximal to predicted 
locations of substrate residues 1 and 3, suggesting that this residue stabilizes the 
orientation of the substrate backbone to facilitate cross-linking (Figure 2-6B).  The sulfur 
atom Met226 may form hydrogen bonds with the phenol hydroxyls on either residues 1 
and/or residue 3 of the substrate aglycone.  Similarly, residue Gln230, which is conserved 
only among P450s that catalyze 1-3 cross-links on glycopeptides, may form hydrogen 
bonds with the phenol hydroxyls on residues 2 or 4 to stabilize the extended substrate 
prior to the coupling reaction. 
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Figure 2-6. (A) Structure of the P450(Biol)-ACP-tetradecanoic acid complex near the 
vicinity of the active showing the F, G, and I helices (in pink), the ACP-bound substrate 
(in green) and catalytically important residues (in magenta). (B) A docking model of the 
putative Orf6* complex with the F, G, and I helices colored in cyan.  This model suggests 
that Met226 and Gln230, which are conserved only among Orf6* orthologues, may play 
roles in steering and stabilizing the extended peptide substrate. 
 
Overall structures of the acyltransferases tAtf and aAtf 
The structures of tAtf and aAtf were determined in complex with the acyl donor substrate 
octanoyl-CoA to the resolution of 2.2 Å (tAtf-occ) and 1.7 Å (aAtf-occ), respectively. 
The two Atfs are highly homologous in both primary sequences (identity: 71%; similarity: 
82%) (Altschul et al., 1997) and three-dimensional structures (RMSD: 1.1 Å over 318 
aligned Cα atoms for the ligand-complexed structures) (Holm and Rosenstrom, 2010) 
(Figure 2-7). For simplicity, the description of the overall structure will be based on the 
high resolution aAtf-occ structure.  
 
The overall structure is composed of two domains of similar sizes, with the amino-
terminal domain (NTD) and the carboxy-terminal domain (CTD) consisting of 
approximately 170 residues and 150 residues, respectively (Figure 2-7). A DALI search 
(Holm and Rosenstrom, 2010)  showed that the overall structure does not have significant 
similarity to any published protein structures in the Protein Data Bank.  
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Figure 2-7. (A) (B) Overall structures of the acyltrasferases in complex with octanoyl-
CoA (aAtf-occ and tAtf-occ). The N-terminal domain is shown in blue; the C-terminal 
domain is shown in purple for α-helices and orange for β-strands. The ligand is shown as 
green ball-and-stick representation. (C) Structure-based sequence alignment of the two 
Atfs. Secondary structures are based on aAtf-occ structure. Identical residues are 
highlighted by black background. Red downward triangles, blue upward triangles, and 
red frames indicate residues that are involved in the interactions with the 3’-
phosphoadenosine-5’-diphosphate, the pantothenoylcysteamine, and the octanoate 
moieties, respectively.  
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The NTD is composed of eight α-helices, α1-α8 (Figure 2-7). It may represent a novel 
fold as no structures similar to these domains are found in the Protein Data Bank. The 
CTD is linked to the NTD through a loop (residues Arg170-Leu172) between helix α8 
and strand β1. It is composed of five α-helices and a twisted five-stranded β-sheet (Figure 
2-8A). The β-sheet is wrapped by the α-helices, with one side open to the NTD (Figure 
2-7). The CTD structure shows only modest similarity to the structure of a glyphosate N-
acetyltransferase (GAT; PDB code: 2JDD) (Siehl et al., 2007) (Figure 2-8B), with an 
RMSD of 2.9 Å over only 86 aligned Cα atoms between tAtf-apo and GAT. Most of the 
structurally similar residues are located in the β-sheet of the two proteins. GAT was 
identified by its overall fold as a member of the GCN5-related N-acetyltransferase 
(GNAT) superfamily (Neuwald and Landsman, 1997; Siehl et al., 2007).  
 
 
Figure 2-8. (A) CTD of aAtf-occ complex structure. α-helices are shown in purple and β-
strands are shown in orange. Octanoyl-CoA is shown as green ball-and-stick 
representation. (B) Structure of glyphosate N-acetyltransferase (GAT; PDB code: 2JDD) 
in complex with acetyl-CoA (aco, colored in green) and 3-Phosphoglyceric acid (3pg, 
colored in cyan).  
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Figure 2-9. CTDs of the structures of (A) aAtf-occ and (B) tAtf-occ. α-helices are shown 
in purple and β-strands are shown in orange. Octanoyl-CoA is shown as green ball-and-
stick representation. 2Fo-Fc  electron density map is shown as blue mesh for the ligands.  
 
Octanoyl-CoA binding of the acyltransferases: CoA moiety 
The structures of tAtf-occ and aAtf-occ show that an octanoyl-CoA molecule is bound to 
the CTDs of these Atfs (Figure 2-7). In both structures the acyl substrate is bound in 
almost identical modes (Figure 2-9). The ligand in the aAtf-occ structure shows 
unambiguous electron density for the entire molecule, while in the tAtf-occ structure the 
ligand shows relatively weaker density for the octanoyl moiety (Figure 2-9). Therefore, 
the dissection of the acyl substrate binding pocket will be based on the aAtf-occ structure.  
 
The polar head group of the CoA molecule, 3’-phosphoadenosine-5’-diphosphate, is 
largely exposed to the solvent (Figure 2-10A). Each of the five α-helices in the CTD 
presents one end to contribute in stabilizing the CoA head group. The contacts between 
the head group and the protein are mostly polar interactions including hydrogen bonds 
and salt bridges, except the hydrophobic interactions between the adenine ring and the 
side chain of Leu295, and between the ribose ring and the side chain of Leu247 (Figure 
2-10B). Both leucine residues are conserved in aAtf and tAtf (Figure 2-7C). The adenine 
ring forms two hydrogen bonds with the main chain oxygen atom of Phe277 (3.4 Å) and 
the side chain oxygen of Ser293 (2.9 Å). The 3’-phosphate group forms a salt bridge with 
the main chain nitrogen atom of Thr294 (2.9 Å). The 5’-diphosphate group forms a 
hydrogen bond with the side chain oxygen of Ser251 (2.6 Å) and several salt bridges with 
the main chain nitrogen atoms of Leu204 (2.8Å), His252 (2.9 Å), and Ile253 (2.9 Å), and 
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the side chain nitrogen atom of His252 (2.7 Å) (Figure 2-10B). All these residues are 
conserved or highly similar in aAtf and tAtf (Figure 2-7C).  
 
Figure 2-10. (A) Surface representation of aAtf-occ structure, showing the highly 
exposed 3’-phosphoadenosine-5’-diphosphate moiety of octanoyl-CoA. Regions from the 
CTD and NTD are colored in purple and blue, respectively. The ligand is shown as green 
ball-and-stick representation. Note that the tail of the octanoate group is visible, as 
indicated by the arrow. (B) Interactions between the 3’-phosphoadenosine-5’-diphosphate 
moiety and aAtf protein. The side chains of the interacting residues are shown as purple 
sticks; the main chain atoms are shown as ball-and-sticks, with the carbon atoms in black. 
Octanoyl-CoA is shown as green sticks. Polar interactions are indicated by dashed lines 
(see text for distances).  
 
The pantothenoylcysteamine moiety of the CoA molecule spans the pocket formed by the 
five α-helices in the CTD (Figure 2-11). It bends at the center of the moiety by 
approximately 90 degrees and travels towards the β-sheets (Figure 2-11). It is 
accommodated mostly by hydrophobic interactions, except for the hydrogen bond 
between the terminal carbonyl oxygen of the pantothenate group and the indole nitrogen 
atom of Trp237 (3 Å), and the hydrogen bond between the cysteamine nitrogen atom and 
the main chain oxygen atom of Ile197 (3 Å) (Figure 2-11). The hydrophobic interactions 
on one side of the pantothenoylcysteamine moiety are contributed by the loop (His196-
Leu204) connecting strand β3 and helix α9, including the contributions from the side 
chains of His196, Ile197, and Leu204, and the main chains of His196-Glu199 and 
Gly202-Leu204. On the other side, the side chains of Trp237, Leu238, Ile 253, and 
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Phe277 provided more hydrophobic interactions (Figure 2-11). All these residues are also 
conserved or highly similar in aAtf and tAtf (Figure 2-7).  
 
 
Figure 2-11. Interactions between the pantothenoylcysteamine moiety and aAtf protein. 
The side chains of the interacting residues are shown as purple sticks; the main chain 
atoms are shown as ball-and-sticks, with the carbon atoms in black. Octanoyl-CoA is 
shown as green sticks.  Polar interactions are indicated by dashed lines (see text for 
distances). 
 
Octanoyl-CoA binding of the acyltransferases: octanoate moiety  
- Implications on the acyl chain specificity determinants  
The thioester bond of the octanoyl-CoA molecule is positioned at the interface of CTD 
and NTD, with the octanoate group pointing into the CTD (Figure 2-7), forming an 
approximately 90-degree angle with the tail of the pantothenoylcysteamine moiety 
(Figure 2-11). Very interestingly, in aAtf the binding site for the pantothenoylcysteamine 
moiety and the octanoate group forms a continuous circle, displaying a donut-shape 
tunnel (Figure 2-12A). The circle starts and ends at C4 of the pantoate moiety. The 
pantothenoylcysteamine moiety and the octanoate group (20 atoms total in the main chain) 
travels along the circle and occupy about three fourth of the round tunnel. The remaining 
room in the tunnel between C8 of the octanoate group and C4 of the pantoate moiety 
appears to be suitable to accommodate around five more main chain atoms (Figure 
2-12A), meaning that an acyl chain of around 13-carbon length could possibly be 
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accommodated. This is in good agreement to a recent report that aAtf cannot accept acyl 
chains longer than 14 carbons (Kruger et al., 2005).  
 
 
Figure 2-12. (A) The round binding tunnel for the pantothenoylcysteamine moiety and 
the octanoate group in aAtf-occ structure as shown by gray surface representation. 
Secondary structures involved in octanoate binding are shown in purple cartoon 
representation. The two “axel” residues are shown as cyan sticks. Octanoate-CoA is 
shown as green ball-and-stick representation. (B) Interactions between aAtf and the 
octanoate group of octanoyl-CoA (green sticks). The side chains of the residues are 
shown as purple sticks; the main chain atoms are shown as ball-and-sticks, with the 
carbon atoms in black. Polar interactions are indicated by dashed lines (see text for 
distances). (C) The round binding tunnel for the pantothenoylcysteamine moiety and the 
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octanoate group in tAtf-occ structure as shown by gray surface representation. The 
coloring is the same as in (A). (D) Superimposition of tAtf-occ (gray) and aAtf-occ 
(purple) structures, showing helix α11 of both structures and the round binding tunnel in 
tAtf-occ. (E) The same superimposed structures as in (D) viewed from the left side in (D).  
 
 
The rotating axis, or “axel”, of the round tunnel, is formed by the side chains of Ile197 
and Leu238, which are located on the opposite faces of the “donut” (Figure 2-12A). 
Starting from the location where the thioester bond is positioned, the outer boundary of 
the acyl chain binding region of the tunnel is defined by helices α9 and α11 and strands 
β3-β5 (Figure 2-12A). The 5-stranded β-sheet in the CTD is twisted between strands β3 
and β4, opening a cleft between the two strands (Figure 2-8A and Figure 2-12A). The 
octanoate group inserts into the pocket through this cleft and toward helix α11. This helix 
forms the boundary for the last portion of the round tunnel between C8 of the octanoate 
group and C4 of the pantoate moiety, presumably defining the path for the tail carbons of 
acyl chains longer than 8 carbon atoms (Figure 2-12A).  
 
The octanoate group is accommodated almost exclusively by hydrophobic interactions, 
except that the carbonyl oxygen forms hydrogen bonds with the main chain oxygen of 
Thr235 and a water molecule (Figure 2-12B). The first four carbons are stabilized by the 
main chains of residues Leu195-Ile197 and Gly234-Ser236, and also the side chains of 
Leu195, His196, Ile197, and Leu238. On the other hand, carbons 5-8 are mainly 
stabilized by the side chains of Tyr209, Leu239, and Trp260, and the main chains of 
Leu256-Arg257. Notably, the major contribution comes from the indole ring of Trp260 
(Figure 2-12B). The indole ring lies parallel and side by side to carbons 5-8, providing 
significant support for the acyl chain binding. Given that it is conserved in aAtf and tAtf 
(Figure 2-7C), the existence of this tryptophan might partly explain the preference of both 
Atfs on acyl chains longer than 5 carbons (Kruger et al., 2005).  
 
All the octanoate-binding residues are conserved or highly similar in aAtf and tAtf 
(Figure 2-7C). tAtf displays a hydrophobic round tunnel similar to that in aAtf (Figure 
2-12C). However, significant difference exists between the tunnels in the two Atfs 
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(Figure 2-12A, C, D, and E). The tunnel in tAtf is discontinuous between C8 of the 
octanoate group and C4 of the pantoate moiety, indicating relatively limited space in this 
region (Figure 2-12C). This is in good agreement with the recent findings that the aAtf 
has the highest activity on lauroyl-CoA, which has 12 carbons in the acyl chain, while the 
best substrate for tAtf is decanoyl-CoA, which has only 10 carbons in the acyl chain 
(Kruger et al., 2005).  
 
Such difference in the acyl binding tunnel of the two Atfs could be attributed to mainly 
two aspects in their structures. First, in tAtf, the axel for the round tunnel is formed by the 
side chains of residues Met240 and Val199, while their equivalents in aAtf are Leu238 
and Ile197, respectively (Figure 2-12A and C). Compared to its equivalent (Leu238), 
Met240 in tAtf inserts deeper along the axel, with the methylthio group pointing towards 
the end of the tunnel, which limits the space in this region (Figure 2-12C). Second, helix 
α11 of tAtf is slightly shifted towards the tunnel axel, inevitably bringing more constrains 
on the end of the tunnel (Figure 2-12D). For example, the side chains of Ile255 and 
Leu258 in tAtf are obviously closer to the tunnel compared to their equivalents (Ile253 
and Leu256) in aAtf (Figure 2-12E).  
 
Putative heptapeptide scaffold binding site in the acyltransferases  
To investigate the activity of the Atfs, the acyl acceptor substrate was prepared by 
deacylating mature teicoplanin using the deacetylase/deacylase Orf2* from the 
teicoplanin biosynthesis pathway, a method reported in a recent study (Truman et al., 
2006). The production of deacylated teicoplanin (DT) was confirmed by LC-MS (Figure 
2-13A and Table 2-3).  Octanoyl-CoA was used as the acyl donor and the activity of tAtf 
was tested. The formation of the product was indicated by a new peak in the LC trace and 
it was confirmed by mass spectrometry to be the re-acylated glycopeptide, octanoyl-
teicoplanin (OT) (Figure 2-13A and Table 2-3). These results confirmed the acylation 
activity of tAtf on the teicoplanin scaffold.  
 
Both aAtf and tAtf were reported to be promiscuous on the glycopeptide scaffold and 
they can accept both the teicoplanin and vancomycin scaffolds with significant activities  
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Table 2-3. Mass spectrometry results for acylation reactions.  
 
 
Calculated 
(g/mole) 
Experimental 
(g/mole) 
Difference 
(g/mole) 
teicoplanin 1877.6 1916.6 39 
deacylated 
teicoplanin 
1723.4 1763.6 40.2 
octanoyl-teicoplanin 1849.5 1888.6 39.1 
vancomycin 1447.4 1448.8 1.4 
octanoyl-
vancomycin 
1573.5 1575.7 2.2 
 
 
Figure 2-13. LC traces of heptapeptides. (A)DT: deacylated teicoplanin; OT: octanoyl-
teicoplanin. (B) OV: octanoyl-vancomycin.  
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(Kruger et al., 2005). I tested the activity of tAtf using octanoyl-CoA and vancomycin, 
and indeed vancomycin was acylated to form octanoyl-vancomycin (OV) (Figure 2-13B 
and Table 2-3).  
 
Attempts of co-crystallizing either of the Atfs with a heptapeptide scaffold have not been 
successful, largely due to solubility issues when mixing the protein and the heptapeptide. 
However, the structures of aAtf-occ and tAtf-occ provide valuable information on the 
putative binding site of the scaffold. They both display a clam-shape overall structure, 
with the NTD and CTD being the two shells and strand β1 being the “hinge” (Figure 
2-14A). As a result, a large “mouth-like” open space exists between the two shells 
(Figure 2-14B). Moreover, the acyl substrate is bound in such a way that the thioester 
bond of the substrate is positioned at the interface of NTD and CTD, directly facing the 
large open space between the two domains (Figure 2-14). We speculate that the 
heptapeptide scaffold binds in this open space, with the sugar moiety of amino acid 4 
(Figure 1-4) in close vicinity to the thioester bond for the acylation reaction to occur.  
 
 
Figure 2-14. The putative heptapeptide scaffold binding site shown as (A) cartoon 
representation and (B) surface representation using the aAtf-occ structure. The NTD and 
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CTD are colored in blue and purple, respectively. Octanoyl-CoA is shown as green 
spheres.  
 
Discussion 
Monooxygenase Orf6* 
In order to facilitate the development of novel glycopeptide antibiotics, we have 
investigated the cytochrome P450 monooxygenase Orf6* that is suggested to be the 
second coupling oxygenase in the biosynthesis of teicoplanin.  Recombinant Orf6* yields 
a UV-visible absorption spectra characteristic of P450 heme-proteins, and indicates the 
existence of a low spin heme state for the substrate-free enzyme. The oxidized form of 
Orf6* can be reduced by sodium dithionite and bound via its heme iron (III) atom to 
imidazole.  The 2.2 Å resolution crystal structure of Orf6* exhibits a typical P450-fold 
with a triangular prism shape. Among the substrate-free structures of known wild type 
P450s, OxyB, OxyC, P450nor, and CYP105D6 show the highest similarity to Orf6*.  
 
Sequence comparisons of all the phenol-coupling P450s involved in glycopeptide 
antibiotics biosynthesis suggest primary sequence conservations that may reflect 
substrate preferences of this subgroup of P450s.  Among these, residues Arg165, Met226, 
and Gln230 are conserved only in Orf6*, Dbv13, and StaG, which catalyze the extra 1-3 
cross-link found in type IV glycopeptides.  The conservations of these residues likely 
reflect their importance in stabilizing the extended peptide substrate of these particular 
P450 enzymes.  The corresponding residues in OxyB, which catalyzes the 4-6 cross-link, 
are Leu174, Ala236, and Asn240, and these residues are absolutely conserved among all 
4-6 cross-linking monooxygenases in the biosynthetic clusters of teicoplanin (Orf7*), 
A47934  (StaH), and A40926 (Dbv12).  These patterns of conservation imply the 
importance of these residues in determining the regiospecificity and timing of the phenol-
coupling P450s.  Further analysis of structure-function relationships will require 
reconstitution of in vitro activities using various synthetic peptide substrates that have 
been singly cross-linked and then coupled to the appropriate peptide carrier domains. 
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Acyltransferases aAtf and tAtf 
The acyltransferases involved in the biosynthesis of teicoplanin-type lipoglycopeptide 
antibiotics are valuable tools for semi-biosynthesis of novel lipoglycopeptide antibiotics. 
Initial attempts of using these acyltransferases combined with other tailoring enzymes to 
synthesize novel lipoglycopeptide derivatives proved to be successful (Kruger et al., 
2005). To understand the mechanism of the acylation reaction and substrate recognition, 
we investigated two such acyltrasferases, aAtf and tAtf, which are involved in the 
biosynthesis of A40926 and teicoplanin, respectively. The structures of these two 
enzymes complexed with octanoyl-CoA provided detailed information on the 
determinants of the acyl chain specificity. The enzymes display a two-domain overall 
topology and the acyl-CoA substrate is bound to the CTD. While the polar head of the 
substrate is largely exposed to solvent, the hydrophobic portion, including the 
pantothenoylcysteamine moiety and the octanoate group, fits into a donut-shape tunnel 
deep in the center of CTD. These two groups occupy approximately three fourth of the 
tunnel. The length of the tunnel suggests that it can accommodate around 13 main chain 
carbon atoms in the acyl chain. On the other hand, a significant contribution for the acyl 
chain binding is provided by the interactions between the indole ring of Trp260 (aAtf) or 
Trp262 (tAtf) and carbons 5-8 in the acyl chain, suggesting that acyl chains shorter than 5 
would have low binding affinity. These observations are in good agreement with recent 
report on the chain length preference of these acyltrasferases.  
 
The octanoyl-CoA complexed structures revealed several residues important for the acyl 
chain binding and provided guidelines for engineering the acyl substrate binding pocket 
to accept different novel substrates. It is plausible to propose that mutating Trp260 to a 
smaller residue, such as alanine, would decrease the acyl chain binding affinity 
significantly. Mutating other hydrophobic residues in the pocket, including Leu195, 
Ile197, Tyr209, Leu238, and Leu239, to alanine, might also decrease the affinity to acyl 
substrates. However, the Ile197Ala and Leu238Ala mutations might have another effect 
on the pocket to allow larger substrates to be tolerated, for example, substrates with 
aromatic rings or large branches. This is because that these two residues insert into the 
center of the round tunnel to form the “axel”, and mutating them to smaller residues 
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might free up the center of the round tunnel and generate a “bun-shape” binding pocket, 
which might accommodate larger substrates. On the other hand, mutating Leu195, Ile197, 
and Leu238, which contribute to stabilizing the first four carbons on the acyl chain, to 
tryptophan or other aromatic residues, may increase the affinity to short chain acyl-CoA 
molecules. These mutations would provide useful information towards the development 
of novel lipoglycopeptides.  
 
Both A40926 and teicoplanin are naturally produced as a mixture of compounds that 
differ almost only in the identities of the acyl chains. These acyl chains range from 10 to 
12 carbons and several of them have a methyl branch after carbon 8 (Figure 2-1). This 
fact may be explained from the structures of aAtf and tAtf complexed with octanoyl-CoA. 
In both structures, the acyl binding tunnel show widened shape near the C8 position 
compared to the rest of the acyl-binding tunnel (Figure 2-15), which may account for the 
tolerance of a methyl branch in this region.  
 
 
Figure 2-15. Side view of the octanoate-binding pocket shown as surface representation 
in the structures of (A) aAtf-occ and (B) tAtf-occ. The octanoate group is shown as green 
ball-and-sticks. For simplicity, most of the remaining part of the octanoyl-CoA molecule 
is not shown.  
 
Forced by extensive hydrophobic interactions in the round tunnel, the octanoyl-CoA 
molecule forms two important turns, one at the center of the pantothenoylcysteamine 
moiety and the second one at the sulfur atom. These two turns restrict the long 
hydrophobic tail within the boundary of the CTD and positions the thioester bond at the 
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interface of CTD and NTD, presumably bringing it near to the target acylation site on the 
acyl chain acceptor. The interface between CTD and NTD resembles the open mouth of a 
clam, with the two domains being the two shells. This open mouth is very likely to be the 
binding site for the heptapeptide scaffold of the acyl chain acceptor. NTD might provide 
the major support for the scaffold binding, with helices α7-8 being the bed for the 
scaffold. There might be conformational change in the overall structure upon scaffold 
binding. For example, the two shells might close up to facilitate the scaffold binding. 
Complex structures of the Atfs with the scaffolds would be required to further understand 
the scaffold binding.  
 
The structures of aAtf-occ and tAtf-occ showed that a conserved histidine residue 
(His196 in aAtf and His198 in tAtf) is in close vicinity of the carbonyl group of the 
octanoate moiety in the acyl-CoA substrate. Its side chain points towards the putative 
scaffold binding cavity in these two structures. Thus it is plausible that this imidazole 
ring would be forced to move away from the cavity upon scaffold binding and swing 
towards the carbonyl group of the octanoate moiety. This would stabilize the carbonyl 
oxygen atom and cause the carbonyl carbon to be vulnerable for a nucleophilic attack 
from the amino group on the acyl acceptor (Figure 2-16). Mutagenesis study and co-
crystal structure with the acyl acceptor substrate would be required to examine the role of 
this histidine in the catalysis.  
 
 
Figure 2-16. Putative mechanism of acylation by aAtf.  
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Chapter 3  Biochemical and structural studies on the catalysis mechanism and 
substrate specificity of a tobacco 4-coumarate:CoA ligase 
 
Abstract 
4-coumarate:CoA ligase (4CL; EC 6.2.1.12) belongs to the ANL superfamily of 
adenylating enzymes that contains three subfamilies: acyl- and aryl-CoA synthetases, the 
adenylating domains of non-ribosomal peptide synthetases, and luciferases. As a central 
enzyme in the phenylpropanoid pathway in plants, 4CL provides precursors for numerous 
important metabolites and regulates the carbon flow in plants. The engineering of 4CL 
has attracted extensive interests, but great challenges exist due to lack of a thorough 
understanding of its catalytic mechanism and substrate-specificity determinants. Here we 
present high resolution crystal structures of Nicotiana tabacum 4CL isoform 2 (Nt4CL2) 
in complex with Mg
2+
 and ATP, with AMP and CoA, and with three different 
hydroxycinnamate adenylate intermediates, including 4-coumaroyl-AMP, caffeoyl-AMP, 
and feruloyl-AMP. Nt4CL2-Mg
2+
-ATP structure displays the adenylate-forming 
conformation, whereas other structures are in the thioester-forming conformation. These 
structures not only represent a rare example of an ANL enzyme captured in both 
conformations, but also reveal several important structural features, including a highly 
ordered P-loop that interacts with the pyrophosphate group of ATP molecule, and the 
mainly hydrophobic CoA tunnel and hydroxycinnamate-binding pocket of a 4CL protein.  
Our structures combined with mutagenesis studies identified several crucial residues 
involved in catalysis, ATP binding, and hydroxycinnamate substrate specificity 
determination. Lastly, we generated a deletion mutant of Nt4CL2, ΔVal341, that 
possesses the unusual sinapate-utilizing activity, and explained the molecular rational for 
this activity through structural study of this mutant.  
 
Introduction 
The phenylpropanoid pathway represents the central biosynthetic nexus for the 
production of an array of plant metabolites including monolignols, phytohormones, 
flavonoids, and phenylpropenes (Hahlbrock and Scheel, 1989). The pathway directs the 
flow of carbon from primary metabolism to diverse secondary metabolism branch 
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pathways. These phenylpropanoids serve a range of functions in planta, including 
providing mechanical support, UV protection, defense against pathogens, and mediating 
interactions with pollinators (Hahlbrock and Scheel, 1989; Lee and Douglas, 1996). 
Several of these metabolites are also of pharmaceutical interest, including the stilbenoid 
resveratrol (lifespan extension) (Richard et al., 2011), the phenylpropene shikimol (a 
precursor in the synthesis of the entheogenic drug MDMA) (Gimeno et al., 2005), and the 
coumarin umbelliferone (antioxidant) (Kanimozhi et al., 2011). Lignin, the polymeric 
product of monolignols, has been the focus of research that targets agro-industrial uses of 
plant biomass (Boudet et al., 2003; Ragauskas et al., 2006). 
 
The core reactions of the general phenylpropanoid pathway start with the deamination of 
phenylalanine (by phenylalanine ammonialyase) to yield trans-cinnamic acid (Figure 
1-6), which is then para-hydroxylated (by cinnamate-4-hydroxylase) to form 4-coumaric 
acid. A second hydroxylation at the C3 position of the phenolic ring (by coumarate 3-
hydrolase) affords caffeic acid. Caffeic acid can undergo O-methylation at C3 to yield 
ferulic acid or additional hydroxylation and O-methylation at C5 to yield sinapinic acid 
(Figure 1-7). A key branching point in the phenylpropanoid pathway is the formation of 
coenzyme A (CoA) thioesters of these hydroxycinnamic acid derivatives catalyzed by the 
enzyme 4-coumarate:CoA ligase (4CL, EC 6.2.1.12), which leads to the  productions of a 
variety of important molecules (Figure 1-6). 
 
4CL proteins play vital roles in regulating carbon flow in plant biosynthetic pathways, as 
their product hydroxycinnamate derived-CoA thioesters serve as precursors for various 
branching pathways of phenylpropanoid synthesis. For example, 4-coumaroyl-CoA is a 
substrate for the first committed step in flavonoid biosynthesis (Cukovic et al., 2001), and 
lignin monomers, including 4-coumaryl alcohol, corniferyl alcohol, and sinapyl alcohol, 
are derived from the hydroxycinnamoyl-CoA thioesters (Boerjan et al., 2003). As the 
level and composition of lignin in plants largely determine the efficiency of biomass 
utilization (Boudet et al., 2003), 4-coumarate:CoA ligases have been studied extensively 
in efforts to produce engineered plants with improved biomass utility. Although 
successful studies have been reported recently (Kajita et al., 1997; Lee et al., 1997; Hu et 
 49 
al., 1999), 4CL engineering remains challenging due to limited knowledge of its catalytic 
mechanism.  
 
 
Figure 3-1. Sequence alignment of 4CL isoforms from different organisms. Nt: 
Nicotiana tobacum; Pt: Populus tomentosa; At: Arabidopsis thaliana; Gm: Glycine max.  
 
Homologs of 4CL occur largely in higher plants, including Glycine max (soybean) 
(Knobloch and Hahlbrock, 1975; Lindermayr et al., 2002), Petunia hgbrida (petunia) 
(Ranjeva et al., 1976), Pisum sativum (pea) (Wallis and Rhodes, 1977), Petroselinum 
crispum (parsley) (Douglas et al., 1987), Solanum tuberosum (potato) (Becker-Andre et 
al., 1991), Pinus taeda (loblolly pine) (Zhang and Chiang, 1997), Nicotiana tabacum 
(tobacco) (Lee and Douglas, 1996),  Populus tremuloides (aspen) (Hu et al., 1998), and 
Arabidopsis thaliana (Ehlting et al., 1999). In many species multiple isoforms are 
expressed in various levels in different tissues and at different development stages.  These 
isoforms display divergent substrate specificity against various hydroxycinnamic acid 
derivatives, as exemplified by the differing substrate profiles for the four isoforms of 4CL 
found in soybean (Lindermayr et al., 2002). Intriguingly, one of these 4CL isozymes, G. 
max 4CL1 (Gm4CL1), is capable of utilizing sinapinic acid as its substrate (Lindermayr 
et al., 2002; Lindermayr et al., 2003), which is unusual because most 4CLs homologs 
lack activity against this metabolite (Becker-Andre et al., 1991; Lee and Douglas, 1996; 
Allina et al., 1998; Hu et al., 1998; Ehlting et al., 1999). The only other 4CL protein with 
activity against sinapinic acid is A. thaliana 4CL4 (At4CL4). Most remarkably, the 
sinapate-utilizing activity of Gm4CL1 and At4CL4 is attributed to the  absence of a 
single amino acid within the active site (a valine between Pro343 and Leu344 of 
Gm4CL1 and a leucine between Val370 and Ala371 of At4CL4) (Figure 3-1) 
(Lindermayr et al., 2003; Hamberger and Hahlbrock, 2004). Deletion of the equivalent 
Val or Leu in other paralogs result in significant activity against sinapinic acid 
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(Lindermayr et al., 2003; Schneider et al., 2003), but the molecular rationale for this 
substrate specificity shift has yet to be determined. 
 
 
 
Figure 3-2. The two-step reaction catalyzed by 4CL enzyme.  
 
Formation of CoA thioesters by 4CL occurs through a two-step reaction mechanism, 
involving the formation of a hydroxycinnamate-AMP anhydride in the presence of ATP 
and Mg
2+
 (adenylation step), followed by nucleophilic attack on the carbonyl carbon of 
the adenylate by the phosphopantetheine thiol of CoA (thioesterification step) to yield the 
product thioester (Cukovic et al., 2001) (Figure 3-2). 4CL belongs to the ANL 
superfamily of adenylating enzymes, which contains three subfamilies: acyl- and aryl-
CoA synthetases, the adenylating domains of non-ribosomal peptide synthetases, and 
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firefly luciferases  (Gulick, 2009). Although they catalyze diverse overall reactions, 
enzymes in the ANL superfamily all function through a two-step reaction scheme, in 
which the first adenylation step is conserved (Figure 3-3). While these enzymes are 
structurally similar, their amino acid sequence similarity is limited to typically less than 
20% identity.  
 
 
 
Figure 3-3. General reaction scheme for the ANL superfamily of adenylating enzymes.  
 
Biochemical and structural biological studies demonstrate that members of the ANL 
superfamily undergo large-scale domain movement in order to facilitate the two catalytic 
partial reactions (McElroy et al., 1967; Bar-Tana and Rose, 1968; Bandarian et al., 2002; 
Gulick, 2009). These conformational changes are induced by the binding of the 
respective substrates for each of the reactions steps, and ANL superfamily members are 
proposed to adopt an adenylate-forming conformation during the first half-reaction, and a 
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thioester-forming conformation during the second step. Only two members in this 
superfamily have been structually characterized in both conformations, including 4-
chlorobenzoyl-CoA ligase from Alcaligenes sp. AL3007 (Gulick et al., 2004; Reger et al., 
2008) and human medium-chain acyl-coenzyme A synthetase ACSM2A (Kochan et al., 
2009), limiting thorough structure-function analysis. In addition, structural data of any 
ANL superfamily enzyme bound to unhydrolyzed ATP is restricted due to either partial 
occupancy of the bound ligand or weak electron density in highly conserved residues that 
are critical for ligand binding . Hence, the lack of structural data for an ANL superfamily 
enzyme in all states corresponding to its reaction coordinate restricts protein engineering 
experiments aimed at expanding the substrate scope of these ubiquitous catalysts.  
 
Here we report the structural, and biochemical studies of isoform 2 of N. tabacum 4CL 
(Nt4CL2), along with further kinetic characterization of site-specific mutants identified 
by the structural data.  We present crystal structures of Nt4CL2 in complex with Mg
2+
 
and ATP (Nt4CL2-Mg
2+
-ATP, 2.3 Å), with AMP and CoA (Nt4CL2-AMP-CoA, 1.6 Å), 
and with different adenylate intermediates, including the anhydrides of 4-coumaroyl-
AMP (Nt4CL2-CMA, 1.6 Å), caffeoyl-AMP (Nt4CL2-CFA, 1.8 Å), and feruloyl-AMP 
(Nt4CL2-FRA, 1.7 Å). Lastly, we have generated a deletion variant at Val341 (ΔVal341) 
that expands the catalytic repertoire of 4CL to accommodate sinapinic acid as a substrate, 
and rationalize this gain-of function mutation through structural analysis of ΔVal341 in 
complex with AMP and CoA (ΔV341-AMP-CoA, 1.8 Å). These structures track each of 
the different conformations that are adopted by an enzyme from the ANL superfamily 
along the reaction coordinate. 
 
Experimental procedures 
Protein Purification  
The expression clone of Nt4CL2 (pCRT7/CT-TOPO) (Beuerle and Pichersky, 2002) was 
a kind gift from Dr. Beuerle. It provides constitutive expression of Nt4CL2. A pre-culture 
of Escherichia coli Rosetta (DE3) transformed with the expression clone was grown 
overnight at 37 
o
C in Luria-Bertani (LB) medium with ampicillin (100 g/ml) and 
chloramphenicol (34 g/ml) and used to inoculate (0.5%, v/v) 1 liter of LB medium with 
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the antibiotics. The resultant culture was grown at 37 
o
C for 20-24 hours. Cells were 
harvested by centrifugation at 3,500g for 25 minutes at 4 
o
C. Cell pellet was resuspended 
in 20 mM Tris, pH 8.0, 500 mM NaCl, 30 mM imidazole, and 10% (v/v) glycerol, flash-
frozen in liquid nitrogen, and stored at -80 
o
C until further use.  
 
Cells were disrupted by four passes through an Avestin C5 Emulsiflex French Press and 
insoluble aggregates and cellular debris were removed by centrifugation at 15, 000 rpm 
for 1 hour. The clarified supernatant was applied to a 5ml HisTrap HP column (GE 
Healthcare) that was charged with nickel sulfate and pre-equilibrated with 20 mM Tris, 
pH 8.0, 1 M NaCl, 30 mM imidazole. The column was rinsed with 10 column volume of 
the same buffer and the protein was then eluted with a linear gradient of imidazole from 
30 mM to 200 mM over 60 ml. Fractions with >90% pure Nt4CL2 protein were pooled 
and concentrated to 4 ml, which was further purified by size-exclusion chromatography 
(Superdex 75 16/60, GE Healthcare) in 20 mM HEPES pH7.5, 100 mM KCl. Protein was 
concentrated to 50-60 mg/ml and aliquoted. The aliquots were flash-frozen in liquid 
nitrogen, and stored at -80 
o
C. Protein concentration was measured by UV absorbance at 
280 nm using the theoretical extinction coefficient of 31.5 mM
-1
 cm
-1
. The final yield of 
Nt4CL2 was approximately 5 mg/L.  
 
Mutagenesis 
Nt4CL2 mutants were generated by Quickchange (Stratagene) site-directed mutagenesis 
using the aforementioned expression clone as template.  The procedures were according 
to the manufacturer, except that mutagenesis PCR reactions were performed using 
Phusion Polymerase (Finnzymes). All the mutant proteins were purified following the 
same protocol described above for wild type Nt4CL2.  
 
Enzyme Kinetics of Wild Type and Mutant Nt4CL2 
The enzymatic kinetics of wild type and mutant Nt4CL2 were measured 
spectrophotometrically as described (Stuible et al., 2000) with a few modifications. 
Briefly, each 200 l reaction contained 100 mM Tris pH 7.5, 2.5 mM MgCl2, 2.5 mM 
ATP, 0.2 mM CoA, and various concentrations of corresponding hydroxycinnamate 
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substrates (4-coumaric acid, caffeic acid, ferulic acid, or sinapinic acid). Enzyme 
concentration was typically 15 nM unless a higher concentration was needed for some 
low activity mutants. The reaction was started by the addition of ATP and monitored 
using Varian Cary 4000 UV-Vis spectrophotometer at 25 
o
C. The formation of the 
thioester products were followed at the wavelengths of 333, 345, 346, and 352 nm for 4-
coumaroyl-CoA, caffeoyl-CoA, feruloyl-CoA, and sinapoyl-CoA, respectively (Beuerle 
and Pichersky, 2002), and the concentration of these products were calculated using the 
corresponding extinction coefficients of 21 mM
-1
cm
-1
, 18 mM
-1
cm
-1
, 19 mM
-1
cm
-1
, and 
20 mM
-1
cm
-1
, respectively (Obel and Scheller, 2000; Yamauchi et al., 2003). Km and Vmax 
were calculated by non-linear regression method using OriginPro 8.5 by OriginLab. The 
final values were averaged from three replicas.  
 
LC-MS Analysis of the Thioester Products 
Overnight reactions were set up at room temperature with wild type Nt4CL2 or the 
ΔV341 mutant and appropriate substrates under following concentrations: 100 mM Tris 
pH 7.5, 2.5 mM MgCl2, 2.5 mM ATP, 0.2 mM CoA, 0.2 mM of corresponding 
hydroxycinnamic substrates (4-coumaric acid, caffeic acid, ferulic acid, or sinapinic acid), 
and 0.2 µM of enzyme. 10 µl of each reaction was subjected to positive/negative-ESI 
LC/MS using Agilent 1100 Series HPLC with a Phenomenex Luna C18 (2) (5μm, 100 Å, 
4.6 mm × 150 mm) column coupled to Agilent LC/MSD Ion Trap XCT Plus mass 
spectrometer. Mobile phases consisted of water (solvent A) and acetonitrile (solvent B). 
A liner gradient of 5-95% B over 18 minutes at a flow rate of 0.4 ml/min was used. LC 
traces were recorded at 260 nm (adenine) and also the corresponding wavelengths for the 
thioester products.  
 
To analyze the adenylate intermediate 4-coumaroyl-AMP, reactions were set up under the 
following concentrations: 100 mM Tris pH 7.5, 2.5 mM MgCl2, 2.5 mM ATP, 0.2 mM of 
4-coumaric acid, and 0.2 µM of wild type Nt4CL2. The reactions were incubated at room 
temperature for indicated time and were then subjected to LC-MS analysis following the 
same protocol as described above, except that LC traces were recorded at 340 nm, at 
which the intermediate absorbs the maximum.  
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Figure 3-4. LC-MS analysis of the thioesters produced by wild type Nt4CL2. A) LC 
traces of reactants and 4-coumaroyl-CoA recorded at 260 nm; B) LC traces of 4-
coumaroyl-CoA, caffeoyl-CoA, and feruloyl-CoA recorded at the indicated wavelengths; 
C) MS spectra of the thioester products. 
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Results 
In vitro Kinetic Analysis of Nt4CL2 Activity 
The enzymatic activity of wild type Nt4CL2 against various hydroxycinnamate substrates 
were assayed spectrophotometrically as described (Beuerle and Pichersky, 2002) with a 
few modifications. For each reaction, progress was monitored by measuring formation of 
the final product thioester, which is a two-step process.  Consequently, the values 
reported here correspond to apparent Vmax, rather than kcat. Kinetic parameters were 
determined for Nt4CL2 using 4-coumaric acid, caffeic acid, and ferulic acid as substrates 
(Table 3-1). The formation of each thioester product was further confirmed by end-point 
analysis using reversed-phase liquid chromatography coupled with mass-spectrometry 
(LC-MS) (Figure 3-4). Nt4CL2 showed the highest activity against 4-coumaric acid 
(Vmax/Km = 44.2), and the lowest activity against ferulic acid (Vmax/Km = 20.7), which has 
a meta-methoxy substituent.  
 
Table 3-1. Kinetic properties of Nt4CL2 against different hydroxycinnamic substrates. 
 
 
 
 
 
 
 
Two Conformations Shown by Nt4CL2 Structures 
The overall architecture of Nt4CL2 is similar to those of other ANL superfamily enzymes 
and consists of a large N-terminal domain (Val8 to Asp434) and a smaller C-terminal 
domain (Lys441 to Ala537) that are connected by a highly flexible linker consisting of 
residues Arg435 through Ile440 (the “hinge loop”). Two different conformations for 
Nt4CL2 are observed in the various co-crystal structures, consisting of an adenylate-
forming and a thioester-forming conformation (Figure 3-5). The two conformations are 
related by a rigid body movement, consisting of a ~140-degree rotation of the C-terminal 
domain along the hinge loop.  Despite the drastic rotational movement, there are minimal 
 
Km 
μM 
Vmax 
nkat/mg 
Vmax/Km 
* 
4-Coumaric acid 1.5 ± 0.4 66.3 ± 4.2 44.2 
Caffeic acid 1.0 ± 0.3 44.2 ± 2.7 44.2 
Ferulic acid 2.9 ± 0.4 59.9 ± 2.2 20.7 
Sinapinic acid 1321.9 ± 103.9 0.3 ± 0.0 0.0002 
nkat/mg: nmole/mg Enzyme ∙ sec 
*Unit: L/g Enzyme ∙ sec 
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changes in the isolated N- or C-terminal domains and the individual domains from each 
of the two conformations can be aligned with an RMSD of less than 0.9 Å for the N-
terminal and 0.6 Å for the C-terminal domains. 
 
The structure of Nt4CL2 in the adenylate-forming conformation (in complex with Mg
2+
 
and ATP) is most similar to that of Luciola cruciata (Japanese firefly) luciferase in 
complex with AMP (PDB code: 2D1Q; sequence identity: 34%; RMSD = 2.0 over 514 
aligned Cα atoms) (Nakatsu et al., 2006). The  thioester-forming conformation of Nt4CL2 
is most similar to the structure of P. tomentosa 4CL1 (Pt4CL1) complexed with an 
adenylate intermediate analog (PDB code: 3NI2; sequence identity: 77%; RMSD = 1.1 
over 528 aligned Cα atoms) (Hu et al., 2010). Our structures of Nt4CL2 append to the 
recently reported structures of Alcaligenes sp. AL3007 4-chlorobenzoate-CoA ligase 
(CBL) (Gulick et al., 2004; Reger et al., 2008) and human medium-chain acyl-coenzyme 
A synthetase ACSM2A (Kochan et al., 2009) as one of three ANL superfamily enzymes 
with crystal structures that have been captured in both conformations.  
 
 
Figure 3-5. Two overall conformations of Nt4CL2. A) Adenylate-forming conformation 
assumed by Nt4CL2-Mg
2+
-ATP complex structure. Mg
2+ 
is shown as gray sphere and 
ATP is shown as yellow sticks. B) Thioester-forming conformation assumed by Nt4CL2-
AMP-CoA complex structure. AMP and CoA are shown as yellow sticks. In both 
A B 
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conformations, N-terminal domain is shown in blue and C-terminal domain is shown in 
purple. Key secondary structures are indicated by arrows.  
 
The Adenylation Conformation Reveals an Ordered P-loop 
In contrast to previously reported ATP-bound structures of enzymes in the ANL 
superfamily (Kochan et al., 2009; Osman et al., 2009), our Nt4CL2-Mg
2+
-ATP complex 
structure displays clear and unambiguous electron density for ATP, Mg
2+
, as well as all 
the ATP-interacting residues, especially those within the pyrophosphate-binding loop (P-
loop) (Figure 3-6). The ATP molecule is located at the interface of the N- and C- terminal 
domains, with the AMP portion lying on the top of the N-terminal domain and the 
pyrophosphate group pointing upwards. The adenosine is enclosed by a highly conserved 
region containing Gln331-Glu337, which is designated as the core motif A5 in the ANL 
superfamily (Marahiel et al., 1997) (Figure 3-7), and a divergent loop containing Ser307-
Leu312. The α-phosphate group is coordinated by the side chains of His237 (core motif 
A4), Thr336 (core motif A5) , and Lys526 (core motif A10), and the main chain 
nitrogens of Ser190 (core motif A3) and Thr336. Notably, Lys526 is the only ATP-
interacting residue that is contributed from the C-terminal domain (Figure 3-6). This Lys 
is a universally conserved residue in the core motif A10 (Figure 3-7), or the adenylation 
catalytic loop, and has been shown to be essential for the adenylation reaction (Gocht and 
Marahiel, 1994; Branchini et al., 2000; Horswill and Escalante-Semerena, 2002; Reger et 
al., 2007) but dispensible for the second half reaction (Branchini et al., 2000; Horswill 
and Escalante-Semerena, 2002). Its close vicinity with the α-phosphate and the ribose 
group in the Nt4CL2-Mg
2+
-ATP structure is consistent with its important catalytic role 
and confirms that the structure represents the  adenylate-forming conformation. As 
expected, the Lys526Ala mutation abolished activity (3-8). In addition, mutations of 
other α-phosphate-binding residues, including His237Ala and Thr336Ala, all 
resulted in impaired catalysis (3-8).  
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Figure 3-6. ATP binding in Nt4CL2-Mg
2+
-ATP complex structure. Electron density map 
of ATP is shown as blue mesh. Mg
2+
 is shown as gray sphere.  
 
 
The pyrophosphate moeity is mainly wrapped by the so-called P-loop containing Ser189-
Lys197 (Figures 3-5A and 3-6). This glycine- and serine-/threonine-rich loop belongs to 
the conserved core motif A3, which is believed to play an important role in orientating 
the pyrophosphate during the adenylation reaction (Chang et al., 1997; Stuible et al., 
2000; Horswill and Escalante-Semerena, 2002), in a manner reminiscent of the common 
Walker A motif in many ATP-/GTP-binding proteins (Saraste et al., 1990). In all prior 
structures of ANL enzymes in the adenylation conformation, the P-loop is partially 
disordered (Conti et al., 1996; Conti et al., 1997; May et al., 2002; Gulick et al., 2004; Du 
et al., 2008; Osman et al., 2009), implying that this loop is highly mobile. In contrast, in 
our Nt4CL2- Mg
2+
-ATP structure, clear and continuous electron density can be observed 
for all residues within this loop (Figure 3-6). Residues within the P-loop form extensive 
hydrogen-bonds with the ATP pyrophosphate through the side chains of Ser189, Thr192, 
Thr193, and Lys197, and the main chain of Gly191. Mutations at residues within this 
region, such as Thr193Ala and Lys197Ala, reduced the catalytic efficiency (Vmax/Km) 
by five- to eight-fold (3-8), confirming the importance of this P-loop in the enzyme 
activity.   
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Figure 3-7. Structure-based sequence alignment of enzymes from the ANL superfamily. 
Secondary structures assignment is based on Nt4CL2 structure and shown below the 
sequences. Conserved core motifs (A1-A10) are shown in red frames. Residues that form 
the hydrophobic CoA-binding tunnel (loop1-loop7) are highlighted in pink. Nt: Nicotiana 
tobacum; Pt: Populus tomentosa; Lc: Luciola cruciata; As: Alcaligenes sp. AL3007; Bx: 
Burkholderia xenovorans; Hs: Homo sapiens; Bs: Bacillus subtilis; Bb: Brevibacillus 
brevis; Bc: Bacillus cereus.  
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Thioester-forming Conformation Results in Drastic Movements of the Catalytic 
Residues and the P-loop  
 
Other than the Nt4CL2-Mg
2+
-ATP complex structure described above, all other Nt4CL2 
co-crystal structures reside in the thioester-forming conformation. As  our Nt4CL2 
structures represent a rare example of an ANL enzyme that is structurally characterized in 
both conformations, these structures provide an ideal model for tracking the differences 
between these two states. For the sake of simplicity, discussions of the overall 
architecture of the thioester-forming conformation will be based on the Nt4CL2-AMP-
CoA structure (Figure 3-5). 
 
As noted previously, the thioester-forming conformation is characterized by a 140-degree 
rotation of the C-terminal domain along the hinge region.  This domain movement results 
in two major differences in the nucleotide-binding pocket. First, the core motif A10 
(harboring the essential Lys526) moves 20Å away from the active site and becomes 
completely exposed to solvent (Figures 3-5 and 3-8). Core motif A8 (Arg435 - Gly444), 
or the thioesterification catalytic hairpin, replaces A10 to form the lid of the active site, 
resulting in an entirely new set of residues that stabilize the bound nucleotide. Specific 
interactions with the ribose are mediated through Arg435, Lys437, and Lys441, and 
Lys441 and Gln446 engage the α-phosphate. The C-terminal domain is stabilized in the 
thioester-forming conformation mainly through hydrogen bonding interactions between 
Arg435 and the backbone oxygen of Leu439 and carboxylate oxygens of Glu447. 
Consequently, the Arg435Ala mutation reduced the catalysis efficiency by 500-fold 
(Table 3-2).  
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Table 3-2. Kinetic properties of Nt4CL2 variants against 4-coumaric acid. 
 
 
 
 
 
 
 
 
 
 
 
As a consequence of the domain movement, a highly conserved Lys residue (Lys441) in 
the motif A8, or the thioesterification catalytic hairpin, is now within close distance (2.9 
Å – 3.3 Å) to the oxygen atoms of the ribose and α phosphate (Figure 3-9), implying a 
crucial role for this residue in the second half reaction. Interestingly, both the position 
and interactions of Lys441 are reminiscent of those of the invariant catalytic residue 
Lys526 in the adenylate-forming conformation. A Lys441Ala mutation completely 
abolished enzyme activity (Table 3-2).  
 
 
Figure 3-8. Domain alternation leads to the movement of the P-loop and the catalytic 
residues. A) Nt4CL2-Mg
2+
-ATP complex structure (adenylate-forming conformation); B) 
Nt4CL2-AMP-CoA complex structure (thioester-forming conformation).  
 
 
Km 
μM 
Vmax 
nkat/mg 
Vmax/Km 
* 
wt 1.5 ± 0.4 66.3 ± 4.2 44.2 
T193A 2.9 ± 0.3 16.6 ± 0.6 5.7 
K197A 13.9 ± 1.8 118.5 ± 4.2 8.5 
H237A 143.4 ± 17.8 33.0 ± 1.3 0.2 
T336A 5.1 ± 1.0 4.7 ± 0.2 0.9 
M344A 520.7 ± 91.8 152.4 ± 17.4 0.3 
R435A 614.9 ± 76.1 50.6 ± 2.8 0.1 
K441A No conversion 
K443A 0.9 ± 0.2 24.5 ± 1.6 27.8 
K526A No conversion 
nkat/mg: nmole/mg Enzyme ∙ sec 
*Unit: L/g Enzyme ∙ sec 
B A 
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The second major difference between the two conformations in the nucleotide-binding 
pocket is the displacement of the P-loop by the thioesterification catalytic hairpin 
(Figures 3-5 and 3-8). Consequently, the P-loop bends upwards and adopts a more closed 
structure. This movement is the only significant difference between the two 
conformations at the N-terminal domain, and displacement of this P-loop by the 
thioesterification catalytic hairpin facilitates the shift to the thioester-forming 
conformation. The side chains of three residues within this hairpin, Leu439, Lys441, and 
Gln446, insert into the pyrophosphate-binding site. As this insertion can only occur 
following pyrophosphate removal, the dissociation of the pyrophosphate group is 
absolutely required for the transition from the adenylate-forming to the  thioester-forming 
conformation.  
 
 
Figure 3-9. Residues interacting with CoA. N-terminal residues are shown in blue, C-
terminal residues are shown in red, except that Lys-441 is shown in brown.  
 
The CoA Binding Tunnel is Formed by Seven Loops 
Structures of ANL enzymes with bound CoA are relatively rare and have not been 
reported for any 4CL proteins prior to this study. In the Nt4CL2-AMP-CoA structure, the 
CoA molecule spans a large portion of the protein between the N- and C-terminal 
domains, with the thiol group pointing into the active site. The sulfur atom is situated 3.6 
Å away from an α-phosphate oxygen, where it would be poised for nucleophilic attack 
onto the anhydride intermediate (Figure 3-9). Clear and continuous electron density, 
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corresponding to the bound CoA ligand can be envisioned within a tunnel formed by 
seven loops (five from the N-terminal and two form the C-terminal domains) (Figure 3-7). 
The adenosine head group of CoA is mostly exposed to solvent and the pantetheine group 
is accommodated in the tunnel through van der Waals contacts (Figure 3-9). The only 
hydrogen bonds with CoA molecule are formed between the diphosphate group and 
residues Lys260 and Lys443 (Figure 3-9). These hydrogen bonds are likely not crucial 
for enzyme activity, as the Lys443Ala mutation has a minimal effect on enzyme 
efficiency (Table 3-2).  
 
A comparison between the adenylate-forming (Nt4CL2-Mg
2+
-ATP) and thioester-
forming (Nt4CL2-AMP-CoA) conformation reveals that the C-terminal domain rotation 
facilitates CoA binding in two ways.  First, two loops that are distal to the CoA-binding 
site in the adenylation conformation are brought to the upper side of the tunnel upon 
domain rotation (Figure 3-9). Second, motif A10, which is inserted deeply into the CoA 
tunnel in the adenylation conformation (Figure 3-8), is displaced upon domain rotation. 
As a result of both of these changes, CoA binding can only occur in the thioester-forming 
conformation. 
 
Nt4CL2 Forms a Stable High Energy Anhydride Complex  
During attempts to characterize the two half-reactions using analytical chromatographic 
methods, recombinant wild-type Nt4CL42 was incubated with ATP and various 
hydroxycinnamates. To our surprise, the resulting (adenylated) acid anhydride products 
were stable for several days at room temperature in the absence of CoA (Figure 3-10). 
Upon addition of stoichiometric concentrations of CoA, the anhydride instantly 
decomposed into AMP and the corresponding hydroxycinnamoyl-CoA (Figure 3-10). 
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Figure 3-10. LC-MS analysis of the adenylate intermediate produced by Nt4CL2. The 
enzyme was incubated with the indicated reagents at room temperature. The MS result of 
4-coumaroyl-CoA is shown in the insert.  
 
 
Inspired by these observations, we carried out co-crystallization of Nt4CL2 in the 
presence of ATP and 4-coumaric, caffeic, and ferulic acids. The resultant structures all 
occupy the thioester-forming conformation and each reveals unambiguous electron 
density to the respective acid anhydride within the active site (Figure 3-11). One 
significant difference with the Nt4CL2-AMP-CoA structure is in the conformation of 
His237 (Figure 3-12), which composes the one-residue core motif A4 (Figure 3-7). In 
presence of CoA the side chain of this residue moves away from the active site to 
stabilize the phosphopanthetheine of CoA (Figure 3-12B). Similar movement of the 
equivalent His has been observed in all CoA- or thioester product-bound structures of 
ANL enzymes (Gulick et al., 2003; Reger et al., 2007; Reger et al., 2008; Kochan et al., 
2009; Hughes and Keatinge-Clay, 2011). The important role of His237 is supported by 
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our mutational studies that demonstrated that the His237Ala mutant had nearly 800-
fold decrease in catalytic efficiency relative to the wild-type enzyme (Table 3-2). 
 
 
Figure 3-11. Electron density map of the bound adenylate-intermediates in Nt4CL2 
structures.  
 
In each acid anhydride complex structure, the hydroxycinnamate moiety is enclosed in a 
hydrophobic pocket composed of a five-stranded β-sheet and two α-helices (Figure 
3-13A and B). The side chain of Ser243 provides the only hydrogen bond interactions 
with the hydroxycinnamate group through the 4-hydroxy group. Additionally, the 
aromatic side chain of Tyr239 engages in stacking interaction with the hydroxyphenyl 
ring (Figure 3-12A) and the main chains of Ile239 and Tyr239 are in van der Waals 
contact with the propanoate moiety. Mutating Tyr239 to Phe increases the Km for the 
hydroxycinnamate substrates by less than ten-fold, whereas a Tyr239Ala mutation 
results in a 100- to 250-fold increase of the Km values (Table 3-2), indicating the 
importance of the stacking interaction in accommodating the substrate.  
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Figure 3-12. Comparison between Nt4CL2-feruloyl-AMP (A) and Nt4CL2-AMP-CoA 
(B) complex structures. For clarity, AMP is not shown in the latter structure.  
 
A comparison of the Nt4CL2 acid anhydride complex structures reveals that the binding 
modes for the hydroxycinnamate moieties are similar. The main chain atoms of Met306 
through Ala309 provide additional contacts with the ligand and define one side of the 
substrate ring-binding site. The substituents at C3 point to the side of Met306 and are not 
located in the vicinity of Val341 (Figure 3-13C), contrary to what  was suggested by 
previous modeling studies (Hu et al., 2010). The α-carbon of Gly308 is only 3.9 Å to C2 
of the hydroxyphenyl ring (Figure 3-13C), which indicates that the enzyme cannot 
tolerate substrates with substituents at C2. The bottom of the substrate-binding pocket is  
B A 
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Figure 3-13. Hydroxycinnamate-binding in Nt4CL2-feruloyl-AMP complex structure. A) 
Hydroxycinnamate-binding pocket is composed of two α-helices (blue) and a five-strand 
β-sheet (green). The bulged loop formed by residues Gly399-Leu342 is shown in red. 
Numbering of the secondary structures is based on Figure 3-7. Feruloyl-AMP is shown 
as sphere-stick representation. The ferulate group is colored in yellow and the adenylate 
group is shown in magenta. B) Surface representation of the hydroxycinnamate-binding 
pocket. C) Residues in the hydroxycinnamate-binding pocket. D) The bulged loop 
formed by residues Gly399-Leu342 protrudes towards position 5 on the 
hydroxycinnamate ring, as indicated by the arrow. Val341 is shown in red.  
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formed by two anti-parallel β-strands, and the side chain of Met344 (located on the 
second strand) points towards the 4-hydroxyl group (3.5 Å distance) (Figure 3-13C). The 
Met344Ala mutation dramatically increases the Km for all three substrates, indicating 
the importance of Met344 in accommodating substrate (Table 3-2). Additionally, four 
residues in this region (Gly339-Leu342) protrude towards the C2’ and C3’ of the 
substrate (Figure 3-13A, C, and D) and presumably accounts for the inability to 
accommodate substrates with substitutions at these positions (such as sinapinic acid). 
 
A comparison between all our Nt4CL2 structures showed that most residues of the 
hydroxycinnamate binding pocket are in the same conformation in our Nt4CL2 structures, 
indicating that the large domain rearrangement and the hydroxycinnamate substrate 
binding have little impact on each other.  
 
 
Figure 3-14. LC-MS analysis of sinapoyl-CoA formation catalyzed by Nt4CL2-ΔVal341. 
The MS result is shown in the insert. 
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Table 3-3. Kinetic properties of Nt4CL2 variants against different hydroxycinnamic substrates. 
 
 4-Coumaric acid  Caffeic acid  Ferulic acid  Sinapinic acid 
 
Km 
μM 
Vmax 
nkat/mg 
Vmax/Km 
* 
 
Km 
μM 
Vmax 
nkat/mg 
Vmax/Km 
* 
 
Km 
μM 
Vmax 
nkat/mg 
Vmax/Km 
* 
 
Km 
μM 
Vmax 
nkat/mg 
Vmax/Km 
* 
wt 1.5 ± 0.4 66.3 ± 4.2 44.2  1.0 ± 0.3 44.2 ± 2.7 44.2  2.9 ± 0.4 59.9 ± 2.2 20.7  1321.9 ± 103.9 0.3 ± 0.0 0.0002 
Y239A 228.1 ± 34.8 16.6 ± 1.2 0.07  257.2 ± 85.5 13.9 ± 2.0 0.05  278.3 ± 89.1 2.8 ± 0.4 0.01  n.m. n.m. n.m. 
Y239F 6.9 ± 0.6 74.5 ± 1.6 10.8  8.4 ± 2.0 48.1 ± 3.3 5.7  30.8 ± 6.8 56.0 ± 4.1 1.8  n.m. n.m. n.m. 
V341G 4.3 ± 2.2 42.9 ± 4.3 10.0  4.3 ± 0.9 33.9 ± 1.5 7.9  4.7 ± 0.8 41.3 ± 1.5 8.8  1230.5 ± 196.6 0.6 ± 0.1 0.0005 
dV341 13.7 ± 2.3 40.1 ± 1.6 2.9  15.4 ± 4.9 21.2 ± 1.6 1.4  31.1 ± 2.1 38.1 ± 0.7 1.2  312.8 ± 24.9 12.9 ± 0.5 0.04 
nkat/mg: nmole/mg Enzyme ∙ sec;  n.m.: not measured 
*Unit: L/g Enzyme ∙ sec 
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An Engineered Nt4CL2 Variant That Can Utilize Sinapinic Acid as a Substrate 
Most 4CLs are unable to utilize the meta-substituted sinapinic acid as a substrate 
(Becker-Andre et al., 1991; Lee and Douglas, 1996; Allina et al., 1998; Hu et al., 1998; 
Ehlting et al., 1999). The only known exceptions are the 4CL1 gene product from G. max 
and the 4CL4 protein from A. thaliana. Multiple sequence alignments of various 4CLs 
demonstrate that both of these paralogs have a single amino acid deletion that 
corresponds to either Val341 or Leu342 of Nt4CL2 (Figure 3-1). Moreover, deletion of 
the equivalent amino acid in canonical 4CLs expands the substrate scope of these 
enzymes to accommodate sinapinic acid as a substrate (Lindermayr et al., 2003; 
Schneider et al., 2003).  
 
 
Figure 3-15. Structure comparison between wild type Nt4CL2 (gray) and ΔVal341 (blue). 
Val341 in the wild type structure is shown in red. Position 5 on the hydroxycinnamate 
ring of feruloyl-AMP (yellow) is indicated by the arrow. 
 
In order to understand the rationale for the expanded substrate scope in the deletion 
variant, we generated Nt4CL2 Val341Ala mutant and the single amino acid deletion 
variant Nt4CL2-ΔV341. Kinetic analysis of both variants demonstrates that only the 
Nt4CL2-ΔV341 deletion variant has appreciable activity with the sinapinic acid substrate 
(Table 3-3 and Figure 3-14). Hence, accommodation of meta-substituted substrates can 
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only be tolerated by alterations of the Nt4CL2 main chain (rather than the side chain) at 
residue 341. In addition, the crystal structure of this deletion variant in complex with 
AMP and CoA was determined to 1.8Å resolution (attempts at co-crystallization with 
sinapate substrate were unsuccessful, presumably due to relatively lower binding affinity) 
(Figure 3-15). Structural analysis of this variant reveals that deletion of Val341 
significantly changes the topology of the hydroxycinnamate binding region. In particular, 
the region containing residues Gly339 to Leu341, which is one residue shorter in this 
variant, has flattened to form an extended β-strand (Figure 3-15). Consequently, the space 
near C3’ of the substrate ring is expanded, and substrates bearing a methoxy substitution 
at this position can be accommodated at the active site. While the substrate scope of this 
deletion variant has been expanded to include sinapate, the mutation also eliminates some 
constrains on smaller substrates (coumarate, caffeate, and ferulate), resulting in an 
increase in the Km values for these substrates by more than ten-fold (Table 3-3).  
 
 
Figure 3-16. Orientation of the ligands bound with Nt4CL2. The structures of Nt4CL2-
MgATP, -CMA, and -AMP-CoA are superimposed and only the ligands are shown. ATP 
is shown in green ball-stick model, 4-coumaroyl-AMP in yellow, and both AMP and 
CoA in magenta. Mg
2+
 is shown as a gray sphere.  
 
 
Discussion 
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Domain Alternation 
The several co-crystal structures of Nt4CL2 presented here establish four distinct 
substrate binding pockets at the active site that accommodate AMP, pyrophosphate, CoA, 
and hydroxycinnamate, respectively (Figure 3-16). The AMP- and hydroxycinnamate-
binding pockets do not change appreciably between the adenylate- and thioester-forming 
conformations, suggesting that there is no obvious correlation between domain 
alternation and the binding of either AMP or the hydroxycinnamate. This notion is also 
borne out by the fact that previously reported structures of ANL enzymes with only AMP 
bound have been observed in both adenylate-forming conformation (Jogl and Tong, 2004; 
Nakatsu et al., 2006) and thioester-forming conformation (Yonus et al., 2008; Kochan et 
al., 2009; Hu et al., 2010).  
 
At the active site, the pyrophosphate-binding pocket is delineated by a highly conserved 
P-loop that is dynamically disordered in most prior ANL enzyme structure. The only two 
reported ATP-bound structures of an ANL enzyme contains either a disordered P-loop 
(Osman et al., 2009) or partial occupancy of the pyrophosphate group (Kochan et al., 
2009). In marked contrast, our Nt4CL2-Mg
2+
-ATP co-crystal structure reveals clear and 
continuous electron density for both the P-loop and for all atoms of the bound nucleotide. 
In the adenylate-forming conformation, the P-loop displays an extended  structure and 
wraps the pyrophosphate, whereas in the thioester-forming conformation, the P-loop 
bends upwards and occludes the pyrophosphate-binding pocket. This movement of the P-
loop is a direct consequence of the C-terminal domain rotation in the thioester-forming 
conformation, suggesting that the transition from the  adenylate-forming conformation 
must be preceded by pyrophosphate dissociation. Notably, all reported structures of ANL 
enzymes with bound ATP are in the adenylation conformation, reinforcing the notion that 
ATP (in particular the pyrophosphate moeity) can only be bound in this conformation 
(Kochan et al., 2009; Osman et al., 2009).  
 
Hydrolysis of the pyrophosphate, however, is not sufficient to drive the transition to the  
thioester-forming confirmation, as complexes of ANL enzymes with their cognate 
adenylate intermediate (Conti et al., 1997; May et al., 2002; Du et al., 2008; Reger et al., 
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2008) or intermediate analog (Nakatsu et al., 2006; Hu et al., 2010), which do not have 
pyrophosphate group bound, are in the adenylate-forming conformation. In contrast, the 
structure of P. tomentosa 4CL1 complexed with an intermediate analog (Hu et al., 2010) 
and the co-crystal structures of Nt4CL2 in complex with various adenylated acid 
anhydrides are observed in the thioester-forming conformation. Hence, neither the 
formation of the adenylated intermediate nor the dissociation of the pyrophosphate group 
is sufficient to prompt the transition of ANL enzymes into the  thioester-forming 
conformation. Following pyrophosphate release, ANL enzymes can adopt either of the 
two conformations, and the population equilibria between the two may vary between 
members. 
 
Subsequent binding of CoA induces the switch to the thioesterification coformation. As 
shown in the Nt4CL2-AMP-CoA structure, the shift to the thioesterification 
conformation results in the recruitment of two loops  from the C-terminal domain to form 
the upper side of the CoA-binding tunnel and the displacement of the core motif A10 to 
unblock the tunnel. Also, several new catalytic residues (Arg435, Lys437, Lys441, and 
Gln446) are brought to the active site to carry out the thioesterification reaction. These 
features are consistent with prior observations that  all CoA or thioester product bound 
structures of ANL enzymes are in the thioesterification conformation (Gulick et al., 2003; 
Reger et al., 2007; Reger et al., 2008; Kochan et al., 2009; Hughes and Keatinge-Clay, 
2011).  
 
In summary, our Nt4CL2 structures provide a clear illustration of the catalytic cycle of an 
acyl-/aryl-CoA ligase. Binding of ATP induces the enzyme to adopt the adenylate-
forming conformation, and the A10 motif catalyzes the adenylation reaction in the 
presence of the acyl/aryl substrate. Upon the finish of the adenylation reaction and the 
release of pyrophosphate group, CoA dictates the enzyme to adopt the thioester-forming 
conformation, bringing new catalytic residues to the active site to carry out the 
thioesterification reaction. Lastly, the thioester product must dissociate before the protein 
can switch back to the adenylate-forming conformation and start a new cycle. This 
domain alternation strategy not only provides two sets of catalytic residues for the two 
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half reactions, but also coordinates the access of substrates and the release of products at 
different stages, which might be important to minimize the probability of reverse reaction 
and thus to increase the reaction efficiency.  
 
Substrate Specificity 
Previous attempts to investigate 4CL substrate specificity relied on sequence comparison 
and structural modelling using other ANL enzyme structures (Stuible and Kombrink, 
2001; Schneider et al., 2003). A recent report of P. tomentosa 4CL1 structures did not 
provide  thorough exploration of the substrate binding pocket due to the lack of structures 
with cognate substrates (Hu et al., 2010). Our three Nt4CL2 structures in complex with 4-
coumaroyl-AMP, caffeoyl-AMP, and feruloyl-AMP allow us to study 4CL substrate 
specificity determinants in greater details.   
 
Nt4CL2 accomadates the hydroxycinnamate substrate mainly through three segments: 
His237-Ser243, Met306-Ala309, and Gly332-Met344. The hydroxyphenol ring is 
sandwiched by the aromatic side chain of Tyr239 and the peptide plane of residues 
Gly332-Thr336. The side chain of Tyr239 plays a crucial role in stabilizing the substrate 
ring. Y239A mutation increases the Km of hydroxycinnamate substrates by 100- to 250-
fold and reduced the overall catalysis efficiency (Vmax/Km) by over 1000-fold. In contrast, 
Y239F mutation only results in less than 10-fold of either Km increase or efficiency 
decrease.  Surprisingly, these results are dramatically different than those reported for P. 
tomentosa 4CL1 (Hu et al., 2010). When the equivalent tyrosine in Pt4CL1 was mutated 
to alanine, the enzyme activity increased, whereas mutating it to phenylalanine caused the 
enzyme to be almost inactive against caffeic acid and ferulic acid. Although Pt4CL1 
activity was measured using an end-point assay at only one substrate concentration and 
we measured Nt4CL2 kinetics using continuous assays at various substrate 
concentrations, such dramatic differences in the mutation effect is unlikely due to the 
different methods.  
 
Our structures show that the 4-hydroxy group of the hydroxycinnamate substrate faces a 
large open space, with the side chain of Ser243 to be the only possible block. Mutating it 
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to alanine or glycine might allow a larger substituent at the para-position of the substrate. 
In contrast, the lateral sides of the pocket apply more constraints on the substrate. 
Residues that line the lateral sides of the hydroxycinnamte pocket determine the size of 
substituents allowed on ortho- and meta-positions of the substrate. On one side, residues 
Met306-Ala309 are lined closely (3.9 Å) against the ortho-position, disfavoring any 
substitution on this position. These residues belong to a loop (Met306-Gly313) between 
β-strand 12 and α-helix 11, which is part of both the adenosine binding pocket and CoA 
tunnel, as described earlier. Therefore, an attempt to changing or deleting any residues in 
this region to accommodate ortho-substituent on this side might risk lowering the affinity 
to ATP or CoA. In contrast, the meta-position of this side is fit into a larger space, thus 
allowing the 3-hydroxy group of caffeate or the 3-methoxy group of ferulate to be 
accommadated on this side. It is noteworthy that accomadation of the methoxy group of 
ferulate is accomplished by redirecting the side chain of Met306. Moreover, this methoxy 
group is very close to the main chains of Gly332 (2.6 Å) and Ser307 (3.8 Å), therefore a 
larger substitution might not be allowed at this position.  
 
The orientation of the caffeate and ferulate groups in our structures confutes the 
prediction proposed in the P. tomentosa 4CL1 study (Hu et al., 2010), further 
underscoring the importance of these structures. Our structures show that the meta-
substituent cannot be oriented to the other lateral side of the substrate pocket because the 
bulged loop (Gly339-Leu342) between α-helix12 and β-strand 14 protrudes towards the 
ortho- and meta- positions on this side and greatly limits the space.  However, a meta-
methoxy substituent can be tolerated on this side after shortening this loop by one residue, 
which flattens this region, as shown by our biochemical and structural analysis on a 
deletion variant Nt4CL2-ΔV341. It might also be possible for this mutant to accept an 
ortho-substitution on this side.  
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Chapter 4  Structures of a novel cyclic diguanylate effector PelD involved in 
pellicle formation in Pseudomonas aeruginosa PAO1
1
 
 
Abstract 
The second messenger bis-(3’-5’) cyclic dimeric guanosine monophosphate (c-di-GMP) 
plays a vital role in the global regulation in bacteria. Here, we describe structural and 
biochemical characterization of a novel c-di-GMP effector PelD that is critical to the 
formation of pellicles by Pseudomonas aeruginosa. We present high-resolution structures 
of a cytosolic fragment of PelD in apo form and its complex with c-di-GMP. The 
structure contains a bi-domain architecture composed of a GAF domain (commonly 
found in cyclic nucleotide receptors) and a GGDEF domain (found in c-di-GMP 
synthesizing enzymes), with the latter binding to one molecule of c-di-GMP. The 
GGDEF domain has a degenerate active site but a conserved allosteric site (I-site), which 
we show binds c-di-GMP with a Kd of 0.5 µM. We identified a series of residues that are 
crucial for c-di-GMP binding, and confirmed the roles of these residues through 
biochemical characterization of site-specific variants. The structures of PelD represent a 
novel class of c-di-GMP effector and expand the knowledge of scaffolds that mediate c-
di-GMP recognition.  
 
Introduction 
Bis-(3’-5’) cyclic dimeric guanosine monophosphate (c-di-GMP) (Figure 1-2) is a central 
regulator, which functions as an intracellular second messenger. In bacteria, this molecule 
confers adaptability to various environmental conditions, by coordinating the transition 
between the motile planktonic state to a sessile state associated with biofilm production 
(Jenal and Malone, 2006; Hengge, 2009; Schirmer and Jenal, 2009). Specifically, c-di-
GMP stimulates the production of adhesins and exopolysaccharide matrix components 
and leads to biofilm formation to protect bacteria from host-defense, starvation conditions, 
and antibiotics (Ryder et al., 2007; Gjermansen et al., 2010). Additional roles for c-di-
                                                          
1
 Parts of this chapter are adapted from the following published article with the permission from the 
publisher:  
 
Li, Z., Chen, J.H., Hao, Y., and Nair, S.K. (2012). Structures of the PelD cyclic diguanylate effector 
involved in pellicle formation in Pseudomonas aeruginosa PAO1. J Biol Chem 287: 30191-30204. 
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GMP include control of cell cycle progression (Duerig et al., 2009), antibiotic 
biosynthesis (Fineran et al., 2007), and expression of virulence genes (Parsek and Singh, 
2003; Dow et al., 2006; Kulesekara et al., 2006; Tamayo et al., 2007). The bacterial 
signaling nodes that respond to the c-di-GMP message present targets for therapeutic 
intervention against pathogens. 
 
Similar to other second messenger pathways, the c-di-GMP control module can be 
generally divided into four components that govern signal generation, degradation, 
recognition, and targeting, respectively (Hengge, 2009). The level of the signal molecule 
is dynamically regulated by the opposing activities of diguanylate cyclases (DGCs) and 
phosphodiesterases (PDEs), which synthesize and degrade c-di-GMP, respectively. DGC 
activity is attributed to proteins that contain a characteristic GGDEF domain (named for 
the single-letter amino acid nomenclature of essential active site residues), while PDE 
activity is associated with either enzymes that contain either an EAL or a HD-GYP 
domain (Ausmees et al., 2001; Paul et al., 2004; Schmidt et al., 2005; Ryan et al., 2006). 
Interestingly, many DGCs have been shown to be subject to allosteric product inhibition, 
which is often caused by c-di-GMP binding to the so-called I-site in the GGDEF domain 
(Chan et al., 2004; Christen et al., 2006; De et al., 2009). The I-site is readily identified 
by the RxxD (Arg-X-X-Glu; where X is any amino acid) motif, which is connected N-
terminally to GGDEF motif through a five-residue linker. These two motifs are antipodal 
to each other in the three-dimensional structure as shown by the structures of PleD from 
Caulobacter vibriodes (Chan et al., 2004; Wassmann et al., 2007) and WspR from 
Pseudomonas aeruginosa (De et al., 2008; De et al., 2009).   
 
Direct recognition of the c-di-GMP signal occurs through an effector component that is 
often linked to a signal input component that regulates cellular functions at transcriptional, 
translational, or post-translational levels (Weber et al., 2006; Merighi et al., 2007; Monds 
et al., 2007; Duerig et al., 2009). Strikingly, c-di-GMP effectors are highly diverse and 
are responsible in the diversity of the cellular functions and processes controlled by c-di-
GMP in bacteria (Hengge, 2009; Schirmer and Jenal, 2009). The effectors identified so 
far encompass a variety of domains that are capable of recognizing c-di-GMP, including 
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the well-characterized PilZ domains (Amikam and Galperin, 2006; Ryjenkov et al., 2006; 
Benach et al., 2007; Merighi et al., 2007), an unusual receiver domain in VpsT from 
Vibrio cholera (Krasteva et al., 2010), the cyclic nucleotide monophosphate binding 
domain in Clp from Xanthomonas campestris (Leduc and Roberts, 2009; Chin et al., 
2010; Tao et al., 2010), the AAA σ54 interaction domain in FleQ from P. aeruginosa 
(Hickman and Harwood, 2008), and a degenerate (non-canonical) EAL domain in FimX 
from P. aeruginosa (Navarro et al., 2009) and in LapD from Pseudomononas fluorescens 
(Newell et al., 2009; Navarro et al., 2011), as well as RNA riboswitches (Sudarsan et al., 
2008). Most of the above-mentioned types of c-di-GMP effectors have been structurally 
characterized, including PilZ-domain-containing proteins (Benach et al., 2007; Gulick, 
2009; Guzzo et al., 2009; Ko et al., 2010), VpsT (Krasteva et al., 2010), Clp (Chin et al., 
2010), FimX (Navarro et al., 2009), LapD (Navarro et al., 2011), and class I and II c-di-
GMP-binding riboswitches (Smith et al., 2009; Smith et al., 2010; Smith et al., 2011). 
 
A distinct class of c-di-GMP effector consists of molecules that can bind c-di-GMP 
through an RxxD motif that resembles the I-site of GGDEF domain of DGCs, but do not 
show catalytic activity as their active sites lack the requisite GGDEF motif. Examples 
include PelD from P. aeruginosa (Lee et al., 2007), CdgG from V. cholera (Beyhan et al., 
2008), and PopA from C. vibriodes (Duerig et al., 2009). In contrast to the effectors 
described in the previous paragraph, biochemical data for I-site-containing c-di-GMP 
effectors is sparse, and there are no crystal structures available for any members of this 
receptor class.  
 
PelD is found in the Pel pathway involved in the formation of pellicles, one of the major 
biofilm types formed by P. aeruginosa (Friedman and Kolter, 2004). The Pel pathway 
synthesizes and exports PEL polysaccharides that play both structural and protective 
roles in P. aeruginosa biofilms (Colvin et al., 2011). This pathway contains seven 
proteins, namely PelABCDEFG, which are highly conserved in diverse microbes 
(Friedman and Kolter, 2004), and have been shown to be functionally conserved (Vasseur 
et al., 2005). Although a few attempts were made to assign functions to the seven proteins 
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(Friedman and Kolter, 2004; Vasseur et al., 2005; Vasseur et al., 2007), the mechanism of 
polysaccharides production by this pathway remains largely unknown. 
 
Interestingly, the pellicle formation of P. aeruginosa was implied to be stimulated by c-
di-GMP (Hickman et al., 2005; Kulesekara et al., 2006). Subsequently, PelD was shown 
to be the receptor of c-di-GMP in the Pel pathway and c-di-GMP binding to PelD is 
essential to pellicle production (Lee et al., 2007). In vivo studies showed that c-di-GMP 
enhanced transcription level of pel genes and deletion of pelD gene rendered P. 
aeruginosa PA14 incapable of producing pellicles (Lee et al., 2007). In vitro biochemical 
assays showed that PelD is the only protein in the Pel pathway that binds c-di-GMP (Lee 
et al., 2007). PelD is predicted to be an inner membrane protein with four trans-
membrane helices and a large cytosolic region (Friedman and Kolter, 2004; Lee et al., 
2007). Remarkably, it is proposed to bind c-di-GMP through an I-site-like motif and thus 
represent a novel family of c-di-GMP-binding proteins (Lee et al., 2007). Mutation of 
residues in the I-site-like motif abolished the binding of PelD to c-di-GMP and in vivo 
assays showed that these PelD mutants lack the ability to restore pellicle formation and 
Congo-red binding by P. aeruginosa PA14, indicating that binding of c-di-GMP to PelD 
is required for pellicle production.  
 
Here, we present structural, biochemical, and mutational analyses of a soluble, cytosolic 
domain of PelD from P. aeruginosa PAO1 that harbors all of the necessary elements for 
c-di-GMP recognition. We have determined the crystal structures of this cytosolic 
domain both alone and in complex with c-di-GMP (each to 2.0 Å resolution), as well as 
that of a deletion variant in complex with c-di-GMP (to 1.7 Å resolution). Utilizing the 
structural data as a guide, we have carried out structure-function analysis of a number of 
residues at the c-di-GMP binding site and have quantitatively assessed their roles in 
ligand binding. The combined structural and biochemical data expand upon the current 
knowledge of c-di-GMP receptors and provide the first structural view of a c-di-GMP 
effector that recognizes cognate ligand only through the I-site. 
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Table 4-1. Data collection, phasing and refinement statistics.  
 
 
Apo PelD 
Native 
Apo PelD 
Hg derivative  
PelD-c-diGMP 
Form I 
PelD-c-diGMP 
Form II 
PelD- loop 
c-di-GMP 
PDB Codes 4ETX  4EUV 4ETZ 4EU0 
Data collection      
Cell dimensions      
a, b, c (Å), β (o) 
60.3, 42.4, 60.5 
112.8 
56.1, 102.3, 103.1 
100.1 
59.5, 41.5, 64.4 
110.9 
70.3, 41.3, 110.9 
95.5 
58.1, 41.4, 62.9 
109.9 
Resolution (Å)
1
 50-2.0 (2.1-2.0) 50-2.6 (2.7-2.6) 50-2.0 (2.07-2.0)  50-2.05 (2.15-2.05) 50-1.7 (1.76-1.7) 
Rsym (%)
2
 4.9 (46.8) 9.2 (74.3) 7.5 (36.5)  6.4 (89.7) 6.0 (30.8) 
I/σ(I) 24.7 (4.0) 12.0 (1.8)  23.0 (2.8) 15.6 (2.3) 19.8 (5.3) 
Completeness (%) 99.8 (99.7) 99.2 (98.8)  99.1 (95.0) 99.7 (99.8) 97.6 (82.5) 
Redundancy 7.4 (6.6) 4.3 (4.2) 6.2 (5.3) 5.8 (5.4) 37.7 (3.1) 
Phasing      
FOM/DM FOM
3
   0.417/0.668    
Refinement       
Resolution (Å) 25.0-2.0    25.0-2.0  25.0-2.05 25.0-1.7  
No. reflections 18,333   18,926   38,272  29,209 
Rwork / Rfree
4
 23.2/28.5    22.0/28.1   23.0/27.7  22.9/26.6 
Number of atoms       
Protein 2,370    2,256 4,536 2,247 
c-di-GMP -   46 92 46 
Water 86   128 140 241 
B-factors       
Protein 22.5   15.9 28.6 11.7 
c-di-GMP -   27.8 46.2 24.8 
Water 28.0   19.3 34.1 25.4 
R.m.s deviations       
Bond lengths (Å) 0.012   0.013 0.013 0.007 
Bond angles () 1.35   1.52 1.51 1.21 
1. Highest resolution shell is shown in parenthesis. 
2. Rsym i - <Ii i where Ii = intensity of the ith reflection and <Ii> = mean intensity. 
3. Mean figure of merit before and after density modification 
4. R- obs|-k|Fcalc obs| and R-free is the R value for a test set of reflections consisting of a random 5% of the diffraction data not used in 
refinement. 
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Experimental procedures 
Protein purification and crystallization  
PelD158-CT was cloned into pET28 vector and expressed in E. coli Rosetta2. Wild type and 
mutant proteins were purified using Ni-NTA affinity column followed by size-exclusion 
chromatography in 20 mM HEPES pH 7.5, 100 mM KCl. Protein was concentrated to 
20-30 mg/ml and kept at 4 
o
C. Protein precipitated when stored in this condition but 
became soluble again at room temperature. Protein concentration was determined by UV 
absorbance at 280 nm using calculated extinction coefficient 11920 M
-1
cm
-1
.PelD158-CT 
crystals were grown by the hanging drop vapor diffusion method at room temperature. 
Each hanging drop contained 1 μl of protein solution and 1 μl of mother liquor. The 
mother liquor conditions are as follows. (i) PelD158-CT apo: 100 mM Tris, pH 8, 200 mM 
MgCl2, and 10% (v/v) PEG 8000; (ii) PelD158-CT wild type in complex with c-di-GMP 
(two molecules in the asymmetric unit): 100 mM Tris, pH 8.5, 200 mM Li2SO4, and 1.26 
M (NH4)2SO4; (iii) PelD158-CT wild type or Δ-loop mutant in complex with c-di-GMP (1 
molecule in the asymmetric unit): 50 mM sodium cacodylate, pH 6.5, 10 mM MgSO4, 
1.3 M Li2SO4. Protein concentration was 2-5 mg/ml in all cases. For co-crystallization, 2 
mM c-di-GMP was incubated with the protein at room temperature for 30 minutes prior 
to crystallization. Crystals were cryo-protected in 15% ethylene glycol before flash-
frozen in liquid nitrogen.  
 
Data Collection and Structure Determination  
Initial crystallographic studies were carried out using a construct that spanned residues 
Ile144 (PelD144-CT) through the C-terminus. Flash cooled crystals of PelD144-CT diffract X-
rays beyond a Bragg spacing of 2.5 Å, using an insertion device X-ray beam line (LS-
CAT, Sector 21ID, Advanced Photon Source, Argonne, IL). A mercury derivative was 
prepared by treating crystals with 5 mM ethylmercury bromide for 24 hours.  
Crystallographic phases were determined by single wavelength anomalous diffraction 
from the mercurial derivative. A four-fold redundant data set was collected at 100K to a 
limiting resolution of 2.6 Å (overall Rmerge= 9.2%, 
shell). All diffraction data were integrated and scaled using the HKL2000 package 
(Otwinowski et al., 2003).  Heavy atom refinement and phase calculation were carried 
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out using PHASER (McCoy et al., 2007) as implemented in the PHENIX software suite 
(Adams et al., 2002; Grosse-Kunstleve and Adams, 2003), followed by density 
modification using DM (Cowtan and Main, 1993) and cycles of automated building using 
ARP/wARP (Perrakis et al., 1999) and manual rebuilding using XtalView (McRee, 1999). 
Continuous electron density could only be observed for two of the four molecules that 
were expected to be in the crystallographic asymmetric unit, and subsequent refinement 
of all models using REFMAC5 (Murshudov et al., 1997) stalled with a free R factor 
greater than 40%. As subsequent inspection of the model revealed that electron density 
for the amino terminus could only be observed starting from Asn158, all further 
crystallographic analysis utilized a construct spanning Asn158 through the C-terminus 
(PelD158-CT). Structures of ligand complexes and deletion variants were determined using 
molecular replacement, as implemented in PHENIX. Ramachandran analysis shows that 
over 90% of the protein main chain dihedral angles are in the most favored regions, and 
the rest in generously allowed regions.  Data collection, phasing, and refinement statistic 
are summarized in Table 4-1. 
 
Analytical Size-Exclusion Chromatography  
Oligomerization of PelD158-CT was examined using analytical size-exclusion 
chromatography (Superdex 200 HR 10/30, GE Healthcare) in 20 mM HEPES pH 7.5, 
100 mM KCl. 600 µl of sample with a protein concentration of 0.5 mg/ml was applied to 
the column. For protein complexed with c-di-GMP or cGMP, 70 µM of c-di-GMP or 10 
mM cGMP was included in the sample, and 10 µM of c-di-GMP or 1 mM cGMP was 
included in the mobile phase. The molecular weight standards were Blue Dextran 
(~2,000,000 Da), beta-amylase (~200,000 Da), Albumin (~66,200 Da), carbonic 
anhydrase (~29,000 Da), and cytochrome c (~12,400 Da), and were all purchased from 
Sigma. 
 
[
32
P]-c-di-GMP binding assay  
[
32
P]-c-di-GMP binding assay was adopted from the method by (Lee et al., 2007) with 
some major modifications. [
32
P]-c-di-GMP was synthesized by YdeH (Zahringer et al., 
2011) using [α-32P]-GTP. It was then incubated with purified wild type PelD158 or each 
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of the mutants that have N-terminal His-tag under the following conditions: 7 nM of 
[
32
P]-c-di-GMP, 30 µM of protein, 50% Ni-NTA agarose beads (GE Healthcare), 10 mM 
Tris pH 7.5, and 50 mM NaCl. The mixture was incubated at room temperature for 30 
minutes and then transferred to a Spin-X 0.22 µm centrifuge tube filter (Costar). The 
remaining beads in the original tube were washed with 50 µl of wash buffer (10 mM Tris 
pH 7.5, and 50 mM NaCl) and were also transferred to the filter. Free [
32
P]-c-di-GMP 
was removed from the mixture by centrifugation. The flow through was collected in the 
2ml centrifuge tube that held the filter insert. The filter was washed twice with 300 µl 
wash buffer and the flow through was collected in the same centrifuge tube. The filter 
insert and the flow through were both counted in the scintillation counter and the fraction 
of bound [
32
P]-c-di-GMP was calculated by dividing the filter counts with the sum of 
both counts.  
 
Isothermal titration calorimetry  
Measurements were carried out on a Nano ITC (TA Instruments - Waters LLC) with 
protein protomer typically at 30 µM in the cell and c-di-GMP at 0.5 mM in the syringe. 
For D370A mutant, protein concentration was 100 µM and c-di-GMP concentration was 
3 mM. An initial 1 µl injection was followed by 24 injections of 2 µl each at 240-second 
intervals. c-di-GMP was synthesized by YdeH using GTP and purified according to the 
method by Zahringer et al, and quantitated based on UV absorbance using extinction 
coefficient of 26 mM
-1
cm
-1
 at 260 nm (Rao et al., 2008). Heat of dilution for c-di-GMP 
was estimated from the last 7-10 injections and subtracted from raw data before fitting 
the binding isotherm in NanoAnalyze (TA Instruments). Curve-fitting was conducted 
using single-independent-site binding model. When using the nominal ligand 
concentration we consistently obtain a stoichiometry of more than 2 c-di-GMP molecule 
per protomer of PelD. This physically unreasonable value of stoichiometry lead us 
suspect that the ligand concentration was overestimated due to the presence of UV-
absorbing contaminants, a similar situation as reported previously (Benach et al., 2007). 
Therefore, the ligand concentration was empirically adjusted by a 2-fold reduction to 
yield a stoichiometry approximately at 1 when using the single-independent-site binding 
model. cGMP or cAMP binding experiments were carried out similarly except that 
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protein concentration was 100 µM and cNMP (Sigma-Aldrich) concentration was 10 mM. 
Curve fitting was conducted using single-independent-site binding model without any 
concentration adjustment.  
 
 
Figure 4-1. Analytical size-exclusion chromatography of PelD158-CT. A) 
Chromatographic traces of PelD158-CT in the absence or presence of c-di-GMP or cGMP 
are shown as indicated. B) Molecular weight standard curve. The molecular weight of 
each standard is indicated. The positions and calculated molecular weight of protein 
samples in A) are indicated. 
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Results  
Overall structures of PelD158-CT  
A series of soluble constructs encompassing the cytoplasmic region of PelD were purified 
and crystallized, and these constructs started from Met105, Leu123, Asp 133, or Ile144 
(PelD144-CT) through the C-terminus, respectively. Crystals of PelD144-CT diffracted 
beyond 2.5 Å resolution and crystallographic phases were determined to 2.6 Å using a 
mercurial derivative. Clear electron density could only be observed for two of the four 
molecules in the crystallographic asymmetric unit and while the quality of the 
experimental map was sufficient to allow building of an initial, near-complete model, the 
structure could not be satisfactorily refined. Subsequent inspection of the model revealed 
that electron density for the amino terminus could only be observed starting from Asn158. 
A new construct encompassing Asn158 through the C-terminus (PelD158-CT) was 
generated and structural analysis was carried out on crystals of both PelD158-CT (2.0 Å 
resolution) and its complex with c-di-GMP in two different crystal forms (form I: 2.0 Å 
resolution, form II: 2.05 Å resolution) (see Table 4-1 for data collection and refinement 
statistics). The structures all occupy the same space group of P21, but with different unit 
cell dimensions and, consequently, different packing. There is one molecule in the 
asymmetric unit of the apo structure and in the form I co-crystal structure, while the form 
II co-crystal structure contacts two molecules in the asymmetric unit that appear to the 
result of crystal packing and are biologically irrelevant, as illustrated by both the small 
contact area between protomers (818 Å
2
) (Krissinel and Henrick, 2007) and the solution 
behavior of PelD158-CT as a monomer, both in the presence or absence of c-di-GMP ligand 
(Figure 4-1) .  
 
While the apo structure is well ordered throughout its entirety, the region between 
Glu251 and Val263 is poorly defined in both of the c-di-GMP complex structures. Hence, 
description of the overall fold will be based on the apo structure unless otherwise stated. 
The structure of PelD158-CT can be clearly divided into two domains of similar size, an N-
terminal domain (composed of Gln158 through Ser309) and a C-terminal domain 
(encompassing Asp318 through Ala454), which are connected by a loop composed of 
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residues Asp310-Ala317 (Figure 4-2A). Binding of the ligand does not induce any local 
or global changes in the structure (Figure 4-2B) and the two structures can be aligned 
with an average RMSD of 1.0 Å over 285 C  atoms.  
 
 
 
Figure 4-2. Overall structures of PelD158-CT. A) Ribbon diagram of the overall structure 
of PelD158-CT illustrating the overall architecture and the secondary structural elements are 
numbered as illustrated. The disposition of the GGDEF domain (blue) and the GAF 
domain (pink) is shown with the I-site colored in green and the A-site GGDEF motif 
colored in cyan . B) Close-up view of the ligand-binding site in the PelD158-CT-c-di-GMP 
co-crystal structure using the same color and numbering scheme as in panel A. The c-di-
GMP ligand is shown as a ball-and-stick with yellow carbon atoms. Binding of the ligand 
does not result in any significant changes in the structure of the protein.  
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Table 4-2. DALI search (Holm and Rosenstrom, 2010) results using the C-terminal 142 residues (313-454) (GGDEF domain) of 
PelD158-CT. 
 
Protein Organism 
PDB 
code 
Z-score 
RMSD
a
 
(Å) 
Sequence 
identity
b
 
References 
FimX Pseudomonas aeruginosa 3HVA 10.6 3.9 15% (124) (Navarro et al., 2009) 
PleD Caulobacter vibrioides   2V0N 9.6 4.1 17% (127) (Wassmann et al., 2007) 
PleD Caulobacter vibrioides   1W25 9.6 3.9 17% (126) (Chan et al., 2004) 
WpsR Pseudomonas aeruginosa 3I5B 9.4 3.7 14% (121) (De et al., 2009) 
XCC4471 Xanthomonas campestris pv. campestris 3QYY 9.2 4.0 15% (121) (Yang et al., 2011) 
WspR P.aeruginosa PAO1 3BRE 9.0 4.0 15% (126) (De et al., 2008) 
LapD Pseudomonas fluorescence Pf0-1 3PJX 8.9 4.3 15% (125) (Navarro et al., 2011) 
a
RMSD: root-mean-square deviation.  
b
Percentage of identical amino acids over all structurally equivalent residues. The number of structurally equivalent residues is 
shown in parenthesis.  
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Table 4-3. DALI search results using the N-terminal 155 residues (158-312) (GAF domain) of PelD158-CT. 
 
Protein Organism 
PDB 
code 
Z-score 
RMSD
a
 
(Å) 
Sequence 
identity
b
 
References 
PDE5A1 Homo sapiens 3MF0 12.7 2.7 13% (127) (Wang et al., 2010) 
Free methionine-R-sulfoxide 
reductase (fRMsR) 
Neisseria meningitidis 3MMH 11.7 2.9 18% (131) (Gruez et al., 2010) 
YebR (fRMsR) Escherichia coli 1VHM 11.3 2.9 17% (129) 
(Badger et al., 2005; 
Lin et al., 2007) 
Histidine kinase DevS Mycobacterium smegmatis 2VKS 11.1 2.6 17% (109) (Lee et al., 2008) 
Ykg9 (fRMsR) Saccharomyces cerevisiae 1F5M 11.0 2.8 18% (128) (Ho et al., 2000) 
Bacteriophytochrome Deinococcus radiodurans 2O9C 10.9 2.9 20% (124) (Wagner et al., 2007) 
Histidine kinase DosS Mycobacterium tuberculosis 2W3G 10.8 3.2 11% (118) (Cho et al., 2009) 
PDE10A Homo sapiens 2ZMF 10.6 3.4 13% (137) (Handa et al., 2008) 
PDE2A Homo sapiens 3IBJ 10.4 11.3 15% (129) (Pandit et al., 2009) 
PDE6C Gallus gallus 3DBA 10.1 3.3 10% (129) (Martinez et al., 2008) 
Bacteriophytochrome Rhodopseudomonas palustris CGA009 2OOL 10.1 3.2 9% (125) (Yang et al., 2007) 
Histidine kinase DosT Mycobacterium tuberculosis 2VZW 9.9 2.8 16% (113) (Podust et al., 2008) 
Bacteriophytochrome Pseudomonas aeruginosa 3G6O 9.6 12.1 12% (143) (Yang et al., 2009) 
cyaB2 Anabaena sp. 1YKD 9.5 3.9 11% (133) (Martinez et al., 2005) 
a
RMSD: root-mean-square deviation.  
b
Percentage of identical amino acids over all structurally equivalent residues. The number of structurally equivalent residues is shown in 
parenthesis. 
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A DALI search (Holm and Rosenstrom, 2010) against the Protein Data Bank using the 
complete structure of PelD158-CT  failed to identify any structure with significant 
similarities over the entire polypeptide. However, a search using either the N- or C-
terminal domains identified several candidates that show significant structural homology 
to each of the individual domains (Tables Table 4-2 and Table 4-3). The PelD N-terminus 
consists of a GAF domain found in various cyclic nucleotide receptors including cyclic-
GMP-regulated phosphodiesterases, adenylyl cyclases. The closest structural homolog is 
the GAF-A of human cyclic GMP (cGMP)-specific 3',5'-cyclic phosphodiesterase 
PDE5A1 (Wang et al., 2010) with an RMSD of 2.7 Å over 128 C  atoms (sequence 
identity: 15%; PDB code: 3MF0). The C-terminus of PelD shows an architecture similar 
to GGDEF domain found in diguanylate cyclases and the closest homolog is the GGDEF 
domain of P. aeruginosa c-di-GMP receptor FimX (Navarro et al., 2009), with an RMSD 
of 3.9 Å over 124 aligned C
Consequently, we refer to the N- and C-terminal domains of PelD158-CT as the GAF and 
GGDEF domains, respectively.  
 
The GGDEF domain of PelD158-CT shows significant differences to canonical 
GGDEF domains  
The GGDEF domain of PelD158-CT is composed of a central four-stranded β-sheet, 
sandwiched between two pairs of α-helices (Figure 4-3A) and is topologically similar to 
other GGDEF domains such as those noted above (Figure 4-3). However, in PelD the 
GGDEF domain is approximately 20-25 residues shorter than the canonical equivalents 
found in these other polypeptides and lacks some of the highly conserved secondary 
structure features (Figure 4-3A and B). For example, a comparison of the GGDEF 
domain of PelD158-CT with that of PleD reveals that the canonical central β-sheet in PleD 
GGDEF domain possesses one extra strand (βi3). Additionally, canonical GGDEF 
domains contain an additional helix (αi1), as well as two additional anti-parallel β-strands 
(βi1 and βi2) that are peripheral to the core structure (Figure 4-3B and C). PelD also lacks 
the catalytically requisite GGDEF sequence characteristic of active DGCs, and instead 
contains RNDEG (Arg376 through Gly380) at the equivalent position (Figure 4-3C). In 
active DGCs such as PleD, this motif is located on a loop between two β-strands and is 
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involved in binding to GTP and metal ion. However, in PelD, both of the β-strands are 
extended and thus occlude the GTP-binding pocket. Even though the two catalytically 
requisite metal-ion-coordinating residues (Asp378, Glu379) are conserved in PelD, they 
point away from the position of the GTP-binding pocket and thus cannot contribute to 
either substrate binding or catalysis. The absence of both the requisite active site residues, 
as well as the additional secondary structural elements found in all active DGCs 
contribute to the lack of a competent active site in the GGDEF domain of PelD. 
 
PelD158-CT binds to c-di-GMP molecule through the I-site  
In the PelD158-CT-c-di-GMP co-crystal structure, one molecule of c-di-GMP molecule is 
bound to the GGDEF domain through the I-site, in an open, shallow pocket, with only 
one guanine ring (Gua-1) in the pocket and the other guanine ring (Gua-2) completely 
exposed to the solvent (Figure 4-4A). The two adenine rings are parallel to each other and 
both vertical to the 12-membered macrocycle formed by two phosphodiester bonds 
between the two GMP molecules, engaging in a two-fold symmetrical clip-shaped 
manner. This binding configuration of c-di-GMP is similar to the one observed in the co-
crystal structures PleD (Chan et al., 2004; Wassmann et al., 2007) and WspR (De et al., 
2008; De et al., 2009), and the PilZ domain VCA0042 from V. cholera (Benach et al., 
2007), but distinct from that in FimX (Navarro et al., 2009) and LapD (Navarro et al., 
2011), where the c-di-GMP ligand adopts an extended conformation and is inserted in a 
deep binding pocket.  
 
The interactions of PelD158-CT with c-di-GMP occur mainly through two segments: a loop 
composed of residues Arg367 through Asp-370, and a β-loop-α segment encompassing 
Leu387 to Arg402. Within these regions, Arg367, Asp370, and Arg402 are responsible 
for the majority of the interactions with c-di-GMP (Figure 4-4B). One of the carboxylate 
oxygen of Asp370 forms a hydrogen bond with N
2
 of Gua-1, and the second forms a 
hydrogen bond with N-1 of Gua-1. The guanidinium nitrogen of Arg402 forms hydrogen 
bonds with O
6
 and N-7 of Gua-1. The guanidinium group of Arg367 inserts under the 
Gua-2 ring and forms hydrogen bonds with the diphosphate backbone, and is in  
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Figure 4-3. GGDEF domains of PelD158-CT and Caulobacter vibriodes PleD. A and B) A 
comparison of the GGDEF domain of (A) PelD158-CT (shown in pink with secondary 
structure numbered as in Figure 1) with that of (B) the active diguanylate cyclase 
Caulobacter vibriodes PleD (shown in gray), with the secondary structural elements that 
are found in most GGDEF domain but are lacking in PelD158-CT shown in magenta. The 
A-site is colored in cyan and the I-site is colored in green. In the PleD co-crystal structure, 
two molecules of the c-di-GMP product stack and occupy the autoinhibitory I-site. C) 
Comparison of secondary structural elements between PelD and PleD near the ligand 
binding sites. The I-site is highlighted in green, the A-site is colored in cyan, and the 
additional secondary structure elements in PleD (αi1, βi1 and βi2) are colored in magenta. 
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Figure 4-4. Cyclic di-GMP binding site in PelD158-CT. A) Stereo-view of electron density 
maps calculated using Fourier coefficients Fobs – Fcalc with phases derived from the final 
refined model of the 1.7 Å resolution co-crystal structure of Δ-loop PelD158-CT with c-di-
GMP. The map was calculated by omitting the coordinates of the cyclic di-GMP prior to 
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mesh). A ribbon diagram of the co-crystal structure is superimposed, and the ligand is 
shown as yellow ball-and-stick and I-site residues Arg-367 and Asp-370 (of the RXXD 
motif) are shown in green. B) Stereo diagram showing the interactions between the cyclic 
di-GMP (in yellow) and PelD residues (in green) that are critical for ligand binding (as 
confirmed by biochemical analysis of site-specific variants; see text for further details). 
Note that Arg-367 wedges between the two guanines and helps to engage the ligand in a 
clip-like fashion. C and D) Comparison of the interactions between cyclic di-GMP and 
the I-site in the co-crystal structures of C) Caulobacter vibriodes PleD and D) 
Pseudomonas aeruginosa WspR. Note that in both of these co-crystal structures, two 
molecules of c-di-GMP stack in order and engage with their respective protein effectors 
in a manner analogous to the interactions provided by Arg-367 in PelD. 
 
 
 
electrostatic proximity with both purine rings (Figure 4-4B). Importantly, Arg367 and 
Asp370 belong to the conserved RxxD motif and is equivalent to the I-sites in the 
GGDEF domain of many DGCs like PleD (Wassmann et al., 2007) and WspR (De et al., 
2009), where the product c-di-GMP binds and allosterically inhibits DGC activity. In 
both of these DGCs, two c-di-GMP molecules are bound as intercalated dimers (Figure 
4-4C and D). The interactions between the RxxD motif and one c-di-GMP are similar to 
those observed in PelD, but intercalated Gua rings stabilize each other in a manner 
similar to the interactions observed between Arg367 and c-di-GMP in the co-crystal 
structure of PelD (Figure 4-4C and D).  
 
Binding affinity of PelD variants to c-di-GMP  
In order to characterize the importance of the residues implicated in c-di-GMP binding in 
our co-crystal structure, we carried out mutagenesis studies and tested the binding affinity 
of wild type and variant PelD proteins to c-di-GMP. Residues Arg367, Asp370, and 
Arg402, which form extensive hydrogen bonds with the ligand, and Tyr399, which 
provides a hydrophobic floor of the binding pocket, were individually mutated to Ala. 
Gly395, which also lines the floor of the binding pocket, was mutated to Pro to introduce 
steric hinderance within the pocket. All these mutants, along with the wild type protein, 
were purified with polyHis tag. The protein variants were immobilized on Ni-NTA 
agarose beads, and their ability to retain [
32
P]-c-di-GMP was tested (Figure 4-5A). 
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Arg367Ala, Tyr399Ala, and Arg402Ala failed to retain c-di-GMP, while the binding 
ability of Asp370Ala was reduced by more than 60%. Gly395Pro bound c-di-GMP at a 
similar level to the wild type.  
 
In order to more accurately quantitatively assess the c-di-GMP binding affinities of 
Asp370Ala and Gly395Pro variants, we conducted isothermal calorimetry titration (ITC) 
analysis (Figure 4-5B) of these two mutants as well as on the wild-type. Wild type 
PelD158-CT binds c-di-GMP at a Kd of approximately 0.5 µM (See Experimental 
Procedures). These results are comparable with previously reported values (Lee et al., 
2007). The Kd for Asp370Ala and Gly395Pro PelD158-CT are 28.6 µM and 3.4 µM, a 60-
fold and 7-fold decrease in the affinity, respectively (Figure 4-5C and D). These results 
confirmed the importance of both Asp370 and Gly395 in c-di-GMP binding, which could 
not be determined directly from the [
32
P]-c-di-GMP binding assay.  
 
As noted, the only significant difference between the structure of unliganded PelD158-CT 
and the two c-di-GMP co-crystal structures is the lack of ordered electron density in the 
region spanning Glu251 and Val263 in the latter. In both crystal forms of the ligand 
bound structure, residues in this loop from the unliganded would clash with a bound c-di-
GMP from a symmetry related molecule. In order to demonstrate that the crystal contacts 
are not physiologically relevant, we generated a deletion variant in which ten residues 
from this loop (Leu249 through His258) were replaced with a Gly-Gly linker (Δ-loop). 
The binding affinity of this mutant was tested using both [
32
P]-c-di-GMP binding assay 
and ITC (Figure 4-5A and E). The Δ-loop variant showed a binding affinity similar to the 
wild type in the [
32
P]-c-di-GMP binding assay, and ITC yielded a Kd of 0.4 µM, which is 
similar to that of the wild type. These results demonstrate that this loop does not interfere 
with c-di-GMP binding and the symmetry-related interactions are a consequence of 
crystal packing. To further corroborate these results, we solved the co-crystal structure of 
the Δ-loop-di-c-GMP complex to 1.7 Å resolution and showed that the binding mode of 
the ligand is identical to that observed in the wild-type structure. 
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Figure 4-5. Binding affinity of PelD158-
CT and variants to c-di-GMP. A) Filter 
binding analysis measuring the relative 
affinity of wild-type and variant PelD158-
CT for [
32
P]-c-di-GMP.  Experiments 
were conducted in triplicate and the 
black bars represent average values with 
associated error bars. Kd values (µM) 
obtained from isothermal titration 
calorimetric experiments are shown on 
top of the corresponding columns.  B) C) 
D) E) Isothermal titration calorimetric 
analysis of the binding of c-di-GMP to 
wild-type PelD158-CT, D370A, G395P, 
and Δ-loop mutants, respectively. The 
binding isotherms for the titration 
experiment (top) and fitted curves based 
on single-independent-site binding 
model (bottom) are shown. 
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GAF domain of PelD158-CT  
The GAF domain is part of various multi-domain proteins that participate in numerous 
signal transduction processes (Aravind and Ponting, 1997; Zoraghi et al., 2004). The 
PelD158-CT GAF domain displays structural similarity to those of cAMP- or cGMP-
specific phosphodiesterases (PDE), including PDE2A (Martinez et al., 2002; Pandit et al., 
2009), 5A(Wang et al., 2010), 6C (Martinez et al., 2008), and 10A (Handa et al., 2008), 
as well as the adenylyl cyclase (AC) CyaB2 (Martinez et al., 2005) (Table 4-3). The GAF 
domains in PDEs and ACs have the capacity to bind cyclic nucleotide (cNMP), including 
cAMP and cGMP, which allosterically regulate the catalytic activity of these enzymes. 
Several PDEs are shown to bind cGMP or cAMP with nanomolar affinities (10-200 nM) 
(Hebert et al., 1998; Huang et al., 2004; Wu et al., 2004; Zoraghi et al., 2005; Heikaus et 
al., 2008; Heikaus et al., 2009) and the cyanobacterial adenylyl cyclases are shown to be 
activated exclusively by cAMP at sub-micromolar concentrations (Martinez et al., 2005).  
 
 
Figure 4-6. Calorimetric analysis of binding affinities of PelD158-CT and the Δ-loop 
variant for cyclic GMP. A and B) Binding isotherms and fitted curves from isothermal 
titration calorimetric analysis of the binding affinity of A) wild-type PelD158-CT and B) Δ-
loop for cyclic GMP. 
 
In order to determine if the GAF domain of PelD158-CT is functional in nucleotide binding, 
we carried out ITC analysis using either cAMP or cGMP. Calorimetric analysis 
demonstrated that PelD158-CT does not bind cAMP with any appreciable affinity (data not 
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shown), and only binds cGMP weakly, with a Kd of  221.7 µM that is several orders of 
magnitude higher than those reported previously for other GAF domains (Figure 4-6A). 
Given the low intracellular concentration of cGMP in bacteria (below 100 nM) (Black et 
al., 1980) and the experimentally determined high Kd value of PelD, the GAF-like 
domain of PelD158-CT likely does not  bind cyclic nucleotides. 
 
A structure-based comparison of the PelD158-CT GAF domain with those of nucleotide-
activated GAF domains reveal several important features that may result in the low 
affinity of PelD158-CT-GAF for cGMP (Figure 4-7). First, in PelD158-CT-GAF a loop that 
connects strand β2 and helix α3 travels through the potential cyclic nucleotide-binding 
pocket and leaves very little room to accommodate any ligands (Figure 4-7A). Second, 
strand βi1 in the GAF domains of PDEs undergoes a significant movement towards the 
ligand pocket upon cGMP binding (Heikaus et al., 2008; Wang et al., 2010). However, 
this strand is absent in PelD158-CT-GAF domain (Figure 4-7A and B). Lastly, several 
residues that are shown to be required for cyclic nucleotide binding are not conserved in 
PelD158-CT-GAF domain (Figure 4-7C). For example, in PDE10A, residues Cys287, 
Phe304, Asp305, Phe352, Thr364, and Gln383 are involved in cAMP binding (Handa et 
al., 2008), but none of these residues are conserved in PelD158-CT-GAF domain. In 
addition, a conserved NKFDE motif (Ho et al., 2000; Martinez et al., 2002; Pandit et al., 
2009) is largely degenerate in PelD158-CT-GAF domain. 
 
Of particular note, the region in PelD158-CT-GAF domain that is disordered in the c-di-
GMP co-crystal structure (Glu251-Val263) corresponds to a portion of the cyclic 
nucleotide binding pocket in the PDEs. The structure of cAMP-bound PDE10A GAF-B 
showed that cAMP molecule is deeply buried in a pocket that uses the antiparallel β-sheet 
as the floor and a short helix (αi1, Asn353-Gly361 in PDE10A) as the roof (Handa et al., 
2008) (Figure 4-7B). To test whether the region between Glu251 through Val263 plays a 
role in to the inability of PelD158-CT to bind cyclic nucleotides, we carried out ITC 
analysis on the Δ-loop mutant with cGMP (Figure 4-6B). The result showed that deleting 
this region led to only a modest increase of the Kd (415.8 µM). Hence, this loop region 
does not play any role in the inability of PelD158-CT GAF to bind ligands.  
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Figure 4-7. GAF domains of PelD158-CT and Phosphodiesterase 10A. A and B) 
Comparison of the GAF domains of A) PelD158-CT (shown in cyan with secondary 
structure numbered as in Figure 1) with the B) human PDE10A-cyclic GMP co-crystal 
structure (shown in brown with ligand colored in green ball-and-stick), with the 
secondary structural elements that are found in most GAF domain but are lacking in 
PelD158-CT shown in magenta. The binding pocket for cyclic GMP is partially occluded in 
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PelD158-CT by the loop that joins β2 and α3.C) Comparison of secondary structural 
elements between PelD and PDE10A near the cyclic GMP binding sites. The I-site is 
highlighted in green, the A-site is colored in cyan, and the additional secondary structure 
elements in PleD (αi1 and βi1) are colored in magenta. Residues in PDE10A that 
involved in direct contact with the cyclic nucleotide are highlighted in yellow and the 
NKFDE motif is highlighted in green. 
 
 
 
We also examined the possibility that PelD158-CT-GAF may mediate homodimerization, a 
typical feature of GAF domains (Heikaus et al., 2009). Analytical size-exclusion 
chromatographic analysis failed to identify any changes in the elution profile of PelD158-
CT in the presence of high concentration of cGMP (Figure 4-1). Although the 
dimerization interface and the domain orientation differ for many GAF domains, they all 
involve the two or three helices (α1, 2, and 4) located on the opposite side of the ligand 
binding pocket (Martinez et al., 2002; Handa et al., 2008; Pandit et al., 2009; Gruez et al., 
2010). However, the corresponding helices in PelD158-CT-GAF domain, consisting of 
residues Gln158-Glu174 (α1), Leu231-Gly240 (α2), and Glu290-Leu307 (α4), are 
oriented towards the GGDEF domain and partly buried in the domain interface (Figure 
4-2).  Thus, the conformation of PelD observed in our structures is not competent to 
mediate dimerization, consistent with the results from our analytical size-exclusion data 
(Figure 4-1).  
 
 
 
Figure 4-8. Multiple sequence alignment of the GGDEF domains discussed in this study 
(see text for further details). The I-site RXXD motif (highlighted in green) and the A-site 
GGDEF motif (in cyan) are shown in bold. The nomenclature of the secondary structural 
elements is based on the PelD structure. 
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Discussion 
The GGDEF domain of PelD158-CT represents a novel class of c-di-GMP receptor that 
binds c-di-GMP through a conserved I-site. GGDEF domains constitute the active sites of 
diguanylate cyclases (DGCs), such as PleD from C. vibriodes (Wassmann et al., 2007), 
WspR from P. aeruginosa (De et al., 2009), and XCC4471 from X. campestris (Yang et 
al., 2011), but are also found in enzymatically inactive c-di-GMP receptors, such as 
FimX (Navarro et al., 2009). The GGDEF domains of PleD and WspR both have an 
active GGEEF motif (A-site) that binds to substrate and catalyzes the cyclization of two 
molecules of GTP into one molecule of cyclic di-GMP. Both PleD and WspR contain a 
conserved RxxD motif (I-site) located amino-terminal to the A-site, and this I-site binds 
to c-di-GMP and accounts for allosteric product inhibition (Wassmann et al., 2007; De et 
al., 2009). In contrast, XCC4471 has a conserved A-site but a degenerate I-site, and 
(competitive) product inhibition is achieved by c-di-GMP binding directly to the A-site 
(Yang et al., 2011). Lastly, the GGDEF domain of FimX is degenerate at both the A-site 
and the I-site, and lacks both DGC activity and c-di-GMP-binding capability (Navarro et 
al., 2009). A similar feature is also observed in another c-di-GMP receptor LapD from P. 
fluorescens (Navarro et al., 2011). Remarkably, distinct from all these domains, the 
GGDEF domain of PelD158-CT has a degenerate A-site (R375NDEG) but a conserved I-site 
(R367GLD) (Figure 4-8). This combination is also conserved in some other potential c-di-
GMP receptors, for example, CdgG from V. cholera (Beyhan et al., 2008), and PopA 
from C. vibriodes (Duerig et al., 2009) (Figure 4-8). Thus the PelD158-CT-GGDEF domain 
is representative of the class of c-di-GMP receptors that contain a degenerate GGDEF 
active site but a conserved I-site that can engage c-di-GMP.  
 
Our structures showed that PelD binds to one molecule of c-di-GMP through the 
conserved I-site in the GGDEF domain. Mutations of the conserved residues in this site, 
Arg367 and Asp370, abolished the binding of PelD to c-di-GMP. Importantly, it was 
shown in previous in vivo studies that such mutants failed to restore the ability of P. 
aeruginosa PA14 to form pellicles and bind Congo red. Combining these functional 
studies and our structural data, a strong correlation may be concluded between the 
binding of PelD to c-di-GMP and the formation of pellicles in vivo.  
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Although the GAF domain of PelD158-CT is topologically similar to canonical GAF 
domains that can bind to cNMP molecules, our calorimetric studies show that PelD158-CT 
does not bind either cAMP or cGMP with affinities that are physiologically meaningful. 
A number of GAF-containing proteins have tandem GAF domains and the two GAF 
domains are proposed to have distinct functions (Heikaus et al., 2009). For example, only 
one of the two GAF domains in PDE2A (GAF-B) binds a cyclic nucleotide, while the 
second domain (GAF-A) lacks ligand-binding ability but is proposed to function as a 
dimerization locus (Martinez et al., 2002; Pandit et al., 2009). cGMP binding to GAF-B 
domain has been shown to allosterically increase the PDE activity at the catalytic domain 
(Martins et al., 1982). A second example is that cGMP binding to GAF-A domain of 
PDE5A stimulates phosphorylation through a cGMP-dependent protein kinase, which in 
turn increases the catalytic activity of PDE5A and cGMP binding affinity of its GAF-A 
domain (Francis et al., 2002; Rybalkin et al., 2003b; Rybalkin et al., 2003a).  
 
Our results showed that the GAF domain of PelD has only very weak affinity to cyclic 
nucleotides, thus it is unlikely regulated by these molecules. On the other hand, the 
location of the PelD158-CT GAF domain between the C-terminal c-di-GMP-binding 
GGDEF domain and an N-terminal transmembrane region implies that it might serve as a 
c-di-GMP signal relay between these two domains. Sequence-based genome analysis 
demonstrates that the association of a GAF domain with a GGDEF domain occurs in 
many diguanylate cyclases (Schirmer and Jenal, 2009). However, only a few of these 
proteins have been biochemically characterized. The diguanylate cyclases DgcA from 
Rhodobacter sphaeroides (Ryjenkov et al., 2005), and MSDGC-1 from Mycobacterium 
smegmatis (Bharati et al., 2012) have been shown to largely lose their DGC activity after 
partial or complete removal of the GAF domain. However, the rationale behind this 
remains elusive, as a ligand-dependent function of the GAF domains in these proteins has 
not yet been established. In the case of DgcA, neither cAMP nor cGMP stimulated DGC 
activity (Ryjenkov et al., 2005).   
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To date, all PDEs that have been structurally characterized form dimers, although the 
functional significance of PDE dimerization remains unclear. The regulatory N-terminal 
region of these proteins, including the tandem GAF domains, are suggested to provide 
dimerization contacts as the isolated catalytic domains from PDE2A (Iffland et al., 2005), 
PDE5A (Sung et al., 2003; Wang et al., 2006), and PDE10A are monomeric (Chappie et 
al., 2007). Unlike the GAF domains found in PDEs, PelD158-CT-GAF domain does not 
form a dimer, neither in the crystal nor in solution. The helices that provide the 
dimerization interface in other GAF domains are partially buried between the GAF and 
GGDEF domains of PelD158-CT, and dimerization through the GAF domain would require 
significant conformational movements.   
 
In most of the characterized receptors, c-di-GMP binding usually induces large 
conformational changes, and these changes have been proposed to propagate signal 
transduction. For example, binding of c-di_GMP to the PilZ domain of VCA0042 from V. 
cholerae induces a 123
o
 rotation, resulting a more compact overall structure and 
drastically different accessible protein surface, which is proposed to interact directly with 
downstream effectors (Benach et al., 2007). Another example is a membrane bound 
effector LapD from P. fluorescens in which autoinhibitory interactions between the 
degenerate EAL and HAMP domains is relieved upon c-di-GMP binding to the EAL 
domain, promoting the interaction of the HAMP domain with other effectors (Newell et 
al., 2009; Navarro et al., 2011). Lastly, c-di-GMP binding to the I-site of two DGCs, 
PleD (Chan et al., 2004; Wassmann et al., 2007) and WspR (De et al., 2008; De et al., 
2009), allosterically inhibits the enzyme activity by forcing the protein dimer into a non-
productive conformation.  
 
Unlike these other c-di-GMP binding targets, c-di-GMP binding to PelD158-CT does not 
result in any structural changes, either globally or local to the ligand-binding site. The 
relative orientation of the GAF and GGDEF domains are retained upon c-di-GMP 
binding, and PelD158-CT remains as a monomer regardless of the absence and presence of 
the ligand. Similarly, the c-di-GMP binding EAL domain from FimX from P. aeruginosa 
is monomeric, and does not undergo any structural changes upon ligand binding (Navarro 
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et al., 2009). It was proposed that c-di-GMP binding might facilitate complex formation 
between the EAL domain and an unidentified binding partner (Navarro et al., 2009). A 
similarly plausible model can also be considered for PelD, and this is further strengthened 
by the fact that c-di-GMP in the complex structure is significantly surface exposed. 
Binding of the ligand might either interrupt the interaction between the PelD GGDEF 
domain and an unidentified binding partner, or bridge the GGDEF domain to its binding 
partner. An example of protein-protein interactions triggered by c-di-GMP was reported 
recently on a PilZ domain-containing protein (Guzzo et al., 2009).  
 
There are a large number of GGDEF domain-containing proteins in bacteria, which have 
diverse functions and thus account in part for the complexity of c-di-GMP signaling. 
While studies have begun to investigate the hierarchy and specificity of GGDEF domain-
mediated signaling pathways (Kader et al., 2006; Sommerfeldt et al., 2009), the 
knowledge of protein binding partners of GGDEF domains is still limited. The binding or 
dissociation of a protein partner to the GGDEF domain might cause a conformational 
change in the N-terminal transmembrane domain of PelD, using the GAF domain as a 
signal relay. A BLAST search (Marchler-Bauer et al., 2009) reveals that the N-terminal 
transmembrane domain of PelD (N-terminus - Ala104) is categorized as a domain of 
unknown function under DUF4118 superfamily (Pfam 13493). Domains in this 
superfamily exist in a wide variety of bacterial signaling proteins, and these may play a 
role in signal transduction. Along with two other proteins in the Pel pathway, PelE and 
PelG (Friedman and Kolter, 2004),  which are predicted to contain transmembrane 
helices, PelD could facilitate the export of carbohydrate-containing substance. Such 
export processes might require interactions between these transmembrane proteins and 
PelC, an outer-membrane lipoprotein that has been shown to facilitate exopolysaccharide 
transport (Vasseur et al., 2007). We are continuing additional biochemical, 
microbiological and structural studies aimed at identifying the effectors downstream of 
PelD that mediate pellicle formation.   
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